The Attenuating Effects of 14-3-3η in Parkinson’s Disease-Related α-Synuclein Aggregation by Ovesen, Mette
 
 
The Attenuating Effects of 14-3-3h in Parkinson’s 
Disease-Related a-Synuclein Aggregation 
 
 
By Mette Ovesen 
 
 
Thesis submitted in partial fulfillment of the requirements for the degree of 
Master of Science 
 
Department of Biological Sciences 
Faculty of Mathematics and Natural Sciences 




The work on this thesis was carried out at the NucReg Group at the Department of Biological 
Sciences, University of Bergen. It should be noted that the Covid-19 pandemic and resulting 
lab-shutdown took place during the work on this thesis, and thus affected it to a certain degree.    
 
A lot of people have contributed to this master project, both directly and indirectly. First of all, 
I would like to thank my co-supervisor Martin Jakubec. Thank you for all your valuable training 
in the lab, teaching me to work independently and for putting up with my many questions, 
always with a smile and positivity. You have been an amazing co-supervisor who I have learned 
so much from. I really appreciate that you took the time answer my questions and assist me in 
the writing process even when it wasn’t your job anymore. This would not have been possible 
without you! 
 
I want to thank my main supervisor Øyvind Halskau, for your support and encouragement 
throughout this entire project. Your enthusiasm, your enlightening albeit sometimes weird 
metaphors, your feedback and guidance in the writing process has been invaluable. Thank you 
for answering e-mails at every hour and somehow always finding time to help. This year has 
been so educating and exciting, and I am grateful that I could be part of your group and this 
very interesting project! I also want to thank my co-supervisor Espen Bariås for helping me 
throughout my thesis work, and Diana Turcu for your assistance with lab work and for taking 
the time to give feedback on my thesis, despite not being my co-supervisor on paper.  
 
The positive working environment in the NucReg group has made this year fun, educational 
and it has been a pleasure being a master student here. Thank you to my friends and fellow 
students for being there through the ups and downs, and for making this year a great experience 
with many great memories! I of course have to thank my family for their continuous support, 
and a give special thanks to my sister for at least pretending to be interested in what I do. Lastly, 
I want to thank the people in charge of the MolBio coffee club, without whom I would surely 





Bergen, June 2020 
Mette Ovesen 
 3 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ................................................................................................................................... 2 
SELECTED ABBREVIATIONS .......................................................................................................................... 5 
ABSTRACT ............................................................................................................................................................. 6 
1. INTRODUCTION .............................................................................................................................................. 7 
1.1 PROTEIN MISFOLDING AND DISEASE ................................................................................................... 7 
1.2 a-SYNUCLEIN AGGREGATION – A HALLMARK OF PARKINSON’S DISEASE ............................... 8 
1.3 THE STRUCTURE AND FUNCTION OF a-SYNUCLEIN ........................................................................ 9 
1.4 FROM DISORDERED MONOMERS TO HIGHLY ORDERED FIBRILS ............................................... 10 
1.5 SEVERAL FACTORS INFLUENCE a-SYNUCLEIN AGGREGATION ................................................. 12 
1.5.1 Lipid association affects a-Synuclein aggregation .............................................................................. 12 
1.5.2 Post-translational modifications of a-Synuclein ................................................................................. 13 
1.5.3 The role of the proteostasis network .................................................................................................... 13 
1.6 THE UBIQUITOUS 14-3-3 PROTEINS ..................................................................................................... 14 
1.6.1 Structural Aspects ................................................................................................................................ 14 
1.6.2 Binding partners and cellular functions .............................................................................................. 15 
1.6.3 14-3-3 Proteins in neurodegenerative disease ..................................................................................... 17 
1.7 AN ISOFORM OF INTEREST – 14-3-3h ................................................................................................... 17 
1.7.1 14-3-3h and its interactions with a-Synuclein ..................................................................................... 18 
1.7.2 The role of 14-3-3h in a-Synuclein aggregation and Parkinson’s disease pathology ........................ 19 
1.8 BIOPHYSICAL METHODS FOR STUDYING PROTEINS IN VITRO ..................................................... 19 
1.8.1 Thioflavin T (ThT) monitored aggregation assays ............................................................................... 19 
1.8.2 Nuclear magnetic resonance (NMR) spectroscopy .............................................................................. 20 
1.9 AIMS AND OBJECTIVES OF THE STUDY ............................................................................................. 21 
2. MATERIALS .................................................................................................................................................... 22 
2.1 CHEMICALS ............................................................................................................................................... 22 
2.2 ISOTOPES ................................................................................................................................................... 23 
2.3 PLASMIDS AND PRIMERS ....................................................................................................................... 23 
2.4 ENZYMES, PROTEINS AND CELLS ....................................................................................................... 23 
2.5 COMMERCIAL REAGENTS, MATERIALS AND KITS ......................................................................... 24 
2.6 INSTRUMENTS AND EQUIPMENT ........................................................................................................ 24 
2.7 COMPUTER SOFTWARE .......................................................................................................................... 25 
2.8 BUFFERS, MEDIA AND SOLUTIONS ..................................................................................................... 25 
2.8.1 Buffers and solutions for protein expression ....................................................................................... 25 
2.8.2 Buffers and solutions for isotope-labeled protein expression .............................................................. 25 
2.8.3 Buffers and solutions for protein purification ...................................................................................... 26 
2.8.4 Buffers and solutions for Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
 ....................................................................................................................................................................... 27 
2.8.5 Buffers for nuclear magnetic resonance spectroscopy ........................................................................ 27 
2.8.6 Thioflavin T (ThT) monitored a-Synuclein aggregation assays .......................................................... 27 
3. METHODS ........................................................................................................................................................ 28 
3.1 a-SYNUCLEIN EXPRESSION AND PURIFICATION ........................................................................... 28 
3.1.1 a-Synuclein expression ........................................................................................................................ 28 
3.1.2 Extraction of periplasmic content ........................................................................................................ 28 
3.1.3 Chromatography purification .............................................................................................................. 28 
3.2 14-3-3h EXPRESSION AND PURIFICATION ......................................................................................... 29 
 4 
3.2.1 14-3-3h Expression .............................................................................................................................. 29 
3.2.2 Cell lysis ............................................................................................................................................... 29 
3.2.3 Chromatography purification .............................................................................................................. 30 
3.3 EXPRESSION OF ISOTOPE-LABELED a-SYNUCLEIN AND 14-3-3h ................................................ 30 
3.4 SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS ......................... 30 
3.5 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY ..................................................................... 31 
3.5.1 Sample preparation .............................................................................................................................. 31 
3.5.2 Acquisition and Processing .................................................................................................................. 31 
3.5.3 NMR Experiments ................................................................................................................................ 32 
3.6 THT-MONITORED a-SYNUCLEIN AGGREGATION ASSAYS ........................................................... 32 
3.6.1 Optimizing salt concentrations ............................................................................................................ 32 
3.6.2 Investigating the influence of 14-3-3h on a-Synuclein aggregation ................................................... 32 
3.7 SURFACE PLASMON RESONANCE (SPR) INTERACTION STUDIES ................................................ 33 
4. RESULTS .......................................................................................................................................................... 35 
4.1 PROTEIN EXPRESSION AND OPTIMIZATION ..................................................................................... 35 
4.1.1 a-Synuclein expression and purification ............................................................................................. 35 
4.1.2 14-3-3h Expression and purification ................................................................................................... 36 
4.2 NUCLEAR MAGNETIC RESONANCE EXPERIMENTS ........................................................................ 38 
4.2.1 Analyzing the a-Synuclein fingerprint spectrum ................................................................................. 38 
4.2.2 Improving the fingerprint spectrum of 14-3-3h ................................................................................... 40 
4.3 THT-MONITORED a-SYNUCLEIN AGGREGATION ASSAYS ........................................................... 42 
4.3.1 Analysis of a-Synuclein fibrillation curves .......................................................................................... 43 
4.3.2 Extraction of kinetic parameters from the two-step aggregation model .............................................. 44 
4.3.3 The effects of 14-3-3h on the lag time of a-Synuclein fibrillation ....................................................... 46 
4.3.4 The effects of 14-3-3h on the rate of a-Synuclein fibrillation ............................................................. 47 
4.3.5 Cumulative analysis of a-Synuclein aggregation and the effects of 14-3-3h ...................................... 49 
4.4 SURFACE PLASMON RESONANCE INTERACTION STUDIES .......................................................... 51 
5. DISCUSSION .................................................................................................................................................... 52 
5.1 a-SYNUCLEIN AND 14-3-3h NMR SAMPLES INDICATE POTENTIAL FOR FURTHER 
CHARACTERIZATION ................................................................................................................................... 52 
5.1.1 HSQC fingerprint of a-Synuclein confirms its disordered state .......................................................... 52 
5.1.2 2H-labeling and TROSY-HSQC improves the sensitivity of 14-3-3h signal detection ........................ 53 
5.2 14-3-3Η AFFECTS THE KINETICS OF a-SYNUCLEIN FIBRILLATION .............................................. 54 
5.2.1 Preliminary curve fitting data suggests 14-3-3h may suppress fibrillation ........................................ 54 
5.2.2 14-3-3h Significantly attenuates fibrillation growth rates and overall fibrillation ............................. 55 
5.3 14-3-3h DOES NOT APPEAR TO BIND MONOMERIC a-SYNUCLEIN .............................................. 57 
5.4 IMPLICATIONS FOR PARKINSON’S DISEASE .................................................................................... 58 
5.5 CONCLUSIONS .......................................................................................................................................... 59 
5.6 FUTURE PERSPECTIVES ......................................................................................................................... 60 
6. REFERENCES ................................................................................................................................................. 62 
7. SUPPLEMENTARY DATA ............................................................................................................................ 67 
 
 5 
SELECTED ABBREVIATIONS  
 
   
AD — Alzheimer’s Disease  
ALS — Amyotrophic lateral sclerosis 
APPW — Average percentage of positive wells 
BSA  — Bovine serum albumin 
CJD — Creutzfeldt-Jakob Disease 
CL — Cell lysate  
CSF — Cerebrospinal fluid  
FAs — Fatty acids  
HD — Huntington’s Disease 
HSQC  — Heteronuclear single quantum coherence spectroscopy  
LB medium — Lysogeny broth medium 
LBs — Lewy bodies  
NAC — Non-amyloid b-component 
NDs — Neurodegenerative diseases 
NFPs — Non-fibrillar products  
NMR — Nuclear magnetic resonance 
PAGE — Polyacrylamide gel electrophoresis 
PC — Periplasmic content 
PD — Parkinson’s Disease 
PN — Proteostasis network 
PTMs — Post-translational modifications 
RU — Response units  
SDS — Sodium dodecyl sulfate 
SEC — Size exclusion chromatography  
SPR — Surface plasmon resonance 
ThT — Thioflavin T 
TROSY — Transverse relaxation-optimized spectroscopy  





Characterized by the progressive loss of dopaminergic neurons, Parkinson’s Disease (PD) is 
one of the most common neurodegenerative diseases (NDs). A pathological hallmark of PD is 
the presence of neuronal inclusions termed Lewy Bodies (LBs). The main component of LBs 
has been identified as a-Synuclein (aS): a small synaptic protein with an intrinsically 
disordered structure in its native state. In parkinsonian brains, aS abnormally aggregates into 
fibrillar b-sheet rich structures that accumulate in LBs. Consequently, the misfolding and 
aggregation of aS has been established as central in PD pathology.  
 
In recent years, several studies in neuroprotection have focused on 14-3-3 proteins – a family 
of adaptor proteins with chaperone activities, consisting of seven human isoforms. With regards 
to PD, several 14-3-3 isoforms have been detected in LBs and shown to interact with PD related 
proteins like aS and Parkin. In particular, the 14-3-3h isoform has been found to co-
immunoprecipitate with aS in parkinsonian brains. Previous aggregation studies have also 
demonstrated that this isoform interferes with aS aggregation by rerouting the fibrillation 
process. Moreover, studies in aging mice overexpressing aS demonstrated an upregulation of 
14-3-3h, altogether indicating a role of 14-3-3h in aS aggregation and PD in general.  
 
In this study, we investigated how 14-3-3h in different aS:14-3-3 ratios affect the kinetics of 
aS aggregation in vitro by Thioflavin T (ThT) monitored aggregation assays. Our findings 
show 14-3-3h to decrease aS fibril growth rate by more than 50% in ratios of 10:1 and 2:1. The 
fibrillation lag time, and thus onset, was not significantly affected by 14-3-3h. However, this 
could be attributed to an insufficient number of replicates, and we concluded that 14-3-3h likely 
attenuates aS fibrillation onset as well. We further sought to locate the 14-3-3h residues 
involved in aS binding by nuclear magnetic resonance (NMR) spectroscopy and to characterize 
the binding by surface plasmon resonance (SPR) experiments. Although time restrictions 
prevented binding site analysis, we found that 2H13C15N-labeling and TROSY-HSQC 
experiments considerably improves the 14-3-3h fingerprint spectrum, enabling future binding 
analysis. SPR experiments indicated no binding of 14-3-3h to monomeric aS, suggesting that 
the binding occurs at oligomeric stages of aS aggregation. In sum, we propose that 14-3-3h 
interacts with aS oligomers to attenuate aS fibril growth, and possibly fibrillation onset. 
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1. INTRODUCTION   
Neurodegenerative diseases (NDs) are a diverse group of diseases involving the progressive 
damage or death of neuronal cells. Different parts of the brain or central nervous system can be 
affected, resulting in clinical symptoms such as cognitive decline, motor deficiencies, dementia 
and ataxia (incoordination, speech impediments)1. Despite their growing incidence, efforts to 
find treatments have yielded little success, and no effective therapies currently exist. While the 
most common NDs are Alzheimer’s disease (AD) and Parkinson’s disease (PD), they also 
include disorders such as Huntington’s disease (HD), Amyotrophic Lateral Sclerosis (ALS) and 
Creutzfeldt-Jakob Disease (CJD)1,2. Although NDs present with diverse symptoms and distinct 
disease progressions, there are certain similarities; (i) they all present in later stages of life, 
making age a large risk factor, (ii) with a few exceptions, each disease has a sporadic and a 
familial variant, and (iii) their pathology can be characterized by synaptic abnormalities and 
neuronal loss1. Another important hallmark of many NDs is the phenomenon of protein 
aggregation, which leads to abnormal cellular protein deposits. Hence, a better understanding 
of the pathways involved in protein aggregation, accumulation and toxicity mechanisms is 
viewed as a promising path to finding therapeutic targets3.  
 
1.1 PROTEIN MISFOLDING AND DISEASE  
 
Several NDs are referred to as proteinopathies, characterized by disease-specific proteins that 
misfold and aggregate into larger insoluble structures2. Although the misfolded aggregates are 
generally inactive, their accumulation can trigger cellular stress responses and inflict 
proteotoxic damage to the cells in question4. Post-mitotic neurons are especially vulnerable to 
this problem4. Despite the different mechanisms and pathways through which proteins may 
aggregate, the final structures are usually fibrous and comprised of misfolded proteins in b-
sheet conformations. Termed amyloids, these aggregates or inclusions are deposited in neurons 
of specific brain regions, ultimately leading to neuronal apoptosis and neurodegeneration3. 
However, the mechanisms mediating neurotoxicity remain enigmatic in the question of ND-
related protein aggregation. Whether the protein aggregates are directly involved in the 
pathogenesis has not yet been determined with certainty. It has been suggested that amyloid 
deposits represent an endpoint of a molecular cascade where the earlier stages are more directly 
linked to the pathogenesis than the final aggregates1,3. Nevertheless, specific aggregating 
proteins have been identified as central players in different proteinopathies (Figure 1.1). 
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Examples include deposits of Tau and Amyloid b found in AD, mutations and accumulation of 




Figure 1.1 – Disease-specific proteins and the affected brain regions in neurodegenerative diseases. 
Protein aggregation has become a hallmark of many neurodegenerative diseases. Disease-specific proteins 
like a-Synuclein, Amyloid b, Huntingtin and Prion proteins are all connected to a neurodegenerative disease 




1.2 a-SYNUCLEIN AGGREGATION – A HALLMARK OF PARKINSON’S DISEASE 
 
PD is the second most common ND in the world today6, affecting an estimated 2% of the 
population above 60 years of age7. As there is currently no cure nor efficient means of early 
diagnosis, the underlying pathogenesis of PD has become an important field of research7,8. 
Characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars 
compacta9, PD leads to clinical symptoms such as resting tremors, rigidity and bradykinesia, as 
well as non-motor symptoms like depression, cognitive decline and eventually mood alterations 
and dementia7. Although no definitive cause of PD has been determined, a hallmark of PD is 
the presence of insoluble inclusions called Lewy Bodies (LBs) in the affected neurons8,9. LBs 
are mainly composed of fibrillar aggregates of aS, a small protein normally found at the pre-
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synaptic terminals10. In addition to aS accumulating in the LBs found in sporadic PD, point 
mutations or gene duplication of aS can also produce a dominant inherited form of the disease: 
familial PD8,10,11. Furthermore, overexpression of wild-type aS in cell-culture systems and 
animal models has led to neurodegeneration in dopaminergic neurons11, altogether pointing to 
a central and possibly causative role of aS in the pathogenesis of PD.  
 
1.3 THE STRUCTURE AND FUNCTION OF a-SYNUCLEIN   
 
Comprised of 140 amino acid residues, aS is a small acidic protein abundantly expressed in the 
human brain and predominantly found in the pre-synaptic terminals12. In its soluble cytosolic 
form, aS is termed an intrinsically disordered protein due to its lack of stable secondary and 
tertiary structures12. aS can be divided into three biochemically and functionally distinct 
regions (Figure 1.2): (i) an amphipathic N-terminal region, (ii) a hydrophobic non-amyloid b-
component (NAC) and (iii) an acidic C-terminal13. Whereas the majority of post-translational 
modifications (PTMs) or truncations occur on its C-terminal region13, the N-terminal region is 
the main site for all known clinical mutations (e.g. A53T, A30P, E46K) that result in familial 
PD, implying its significance in the misfolding and aggregation of aS6. Furthermore, the N-
terminal is also where the protein interacts with phospholipid membranes and micelles13. The 
NAC region is also deemed important in the self-aggregation of aS; a stretch of 12 residues in 





Figure 1.2 – The protein sequence and different regions of the intrinsically disordered a-Synuclein (aS). 
This small, acidic protein can be divided into three distinct regions; the N-terminal region (blue), the Non-
Amyloid Component (NAC) region (orange) and the acidic C-terminal region (green)13. Known clinical 
mutations involved in PD have all been found to occur in the N-terminal region, such as A30P, E46K and 
A53T (red), while the NAC region is highly involved in the self-aggregation of aS6. Figure created in 
BioRender.com, and adapted from Miraglia et al13. 
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Hitherto, no exact native function of aS has been uncovered. However, it is not considered an 
essential protein. Knockout studies in mice demonstrated that aS deficiency did not obstruct 
their basic brain functions nor affect their survival14. Nevertheless, aS localization and 
interactions with membranes suggest its involvement in regulation of synaptic plasticity, 
neurotransmitter release, dopamine metabolism and vesicle trafficking15. Interestingly, aS 
interacting with membranes is not only thought to be important for its function. The interaction 
also produces a conformational change in the protein itself. Upon membrane binding, aS can 
transition from its disordered state into a helical conformation12. Depending on the membrane 
lipid constitution, membrane-bound aS can adopt one of two proposed structural models: (i) 
the “extended helix”, comprising one single ~100-residue a-Helix, and (ii) the “horse-shoe”, 
made up of two separate helices with different lipid affinities16. As such, aS exists in healthy 
cells either as cytosolic and disordered or helical and membrane-bound.  
 
1.4 FROM DISORDERED MONOMERS TO HIGHLY ORDERED FIBRILS  
 
In contrast to the unfolded state of native aS, the proteinaceous aggregates found in LBs are 
highly ordered. The aS amyloid fibrils are filamentous in structure and comprised of parallel 
b-sheets, with a cross-b diffraction pattern and a hydrophobic core – characteristics shared with 
fibrillar accumulations found in several other NDs17,18. Because amyloid fibril formation is a 
common occurrence in vitro, it has enabled extensive research on the general fibrillation 
process17. As such, aS fibrillation is now thought to occur through a nucleation-polymerization 
model19. This model implies that soluble monomeric aS form oligomeric species in a primary 
nucleation, before these oligomers form protofilaments that will finally constitute the mature 





Figure 1.3 – Aggregation of a-Synuclein (aS) occurs through a nucleation-polymerization model to form 
fibrillar structures. The primary nucleation occurs when misfolding of the intrinsically disordered and 
soluble aS monomers forms oligomeric species, which are further polymerized to short protofilaments with 
a high b-sheet content. Subsequent fibril elongation then occurs through a secondary nucleation; 
incorporation of new monomers enables fibril growth and finally produces the mature insoluble fibrils17.  
Figure created in BioRender.com.  
  
Fibril growth is enabled by the addition of soluble monomers rather than oligomers, in a process 
termed secondary nucleation17,20. The result is a sigmoidal growth profile with three 
characteristic phases (Figure 1.4). During the lag phase, monomers oligomerize to form the 
larger oligomeric species. This is followed by the growth phase, when protofilaments and fibrils 
are constructed from oligomers and elongated by monomers. Finally, the plateau phase is 
reached, upon which fibril growth is haltered as monomers become depleted17. Additionally, 
preformed fibrils, termed seeds, can enhance aS aggregation in vivo in a process termed 
seeding. Studies of wild-type mice showed that injection of exogenous fibril seeds induced the 
aggregation of their endogenous aS, leading to a pathology resembling the neurodegenerative 
pattern of PD21. If seeds are present, the lag phase can be drastically reduced, and can accelerate 
the growth phase and the overall conversion from soluble to aggregated protein, either through 
elongation or surface-catalyzed secondary nucleation20. Although the amyloid fibril assembly 
has been widely characterized, knowledge of the early oligomerization steps is still limited17. 
Understanding these mechanisms is of great importance – the mechanisms of early 
oligomerization are not only crucial to aS self-association, but oligomeric species have recently 





species Protofilaments b-Sheet rich 






Figure 1.4 – Fibrillation of a-Synuclein (aS) follows a characteristic sigmoidal growth profile. The 
kinetics of aS aggregation can be divided into three distinct phases: (i) oligomerization of misfolded aS 
monomers into the first oligomeric nuclei gives rise to the lag phase, (ii) the growth phase where 
protofilaments are formed and fibril growth occurs through incorporation of monomers, and (iii) the plateau 
phase, characterized by the stagnation of fibril growth as monomers are depleted17. Figure created in 
BioRender.com. 
 
1.5 SEVERAL FACTORS INFLUENCE a-SYNUCLEIN AGGREGATION  
 
In general, multiple factors can influence protein aggregation – temperature, solution 
conditions, protein concentrations and chemical modifications can all affect the pathways and 
kinetics of an aggregating protein24. With regards to aS, more specific events can also modulate 
the self-association of this intrinsically disordered protein.  
 
1.5.1 Lipid association affects a-Synuclein aggregation   
As previously mentioned, interaction with lipid membranes causes a conformational change in 
aS, so it is clear that lipids influence the structure of the protein. However, experiments with 
monomeric aS and lipid vesicles or membranes also indicate that interaction with membranes 
could substantially enhance aS aggregation, a phenomenon referred to as membrane-induced 
aggregation25. In conditions with low lipid:aS ratios, the primary nucleation becomes greatly 
enhanced by aS-lipid interaction. This could be attributed to a high local concentration of aS 
bound to the lipid surface, where monomers are added from solution, or to a conformational 
change that may favor nucleation26. Conversely, it has been suggested that lipid binding could 
inhibit nucleation and further aggregation in conditions where lipid:aS ratios are high. The 
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strong association with a lipid bilayer then stabilizes the helical aS conformation and reduces 
the amount of aS monomers available for nucleation27. Furthermore, the length of fatty acyl 
chains in the membrane-constituting lipids affects the membrane-binding and aggregation 
propensity of aS. Indeed, lipids with short, saturated fatty acyl chains have been implied to be 
a strong contributor to membrane-induced aS aggregation28.  
 
1.5.2 Post-translational modifications of a-Synuclein  
 
Today, an increasing body of evidence suggests that PTMs of aS could play a key role in the 
oligomerization and fibrillation of aS as well as LB formation in PD. Phosphorylation in 
particular has received special attention, as the most prominent modification associated with 
aS aggregation is its phosphorylation at S129. aS containing this modification has been 
identified as the primary component of LBs found in PD brains29, suggesting that it could 
stimulate abnormal aS aggregation. Furthermore, PPA2, a phosphatase that dephosphorylates 
S129, has been demonstrated to attenuate the formation of aS aggregates in aging mice brains30. 
However, some PTMs appear to mediate opposite effects; sumoylation of aS is suggested to 
have a neuroprotective role in PD29. Indeed, the sumoylation of aS in vitro led to a reversal of 
its accumulation and fibrillation, while inhibiting sumoylation caused aS inclusions and 
neurotoxicity in mouse models31.   
 
1.5.3 The role of the proteostasis network  
 
The general folding process is not without error. Considering that any polypeptide could 
theoretically adopt a gargantuan number of possible conformations, mistakes are bound to occur 
even under normal cellular conditions32. For this reason, a complex network of molecular 
chaperone proteins acts to control initial folding processes, conformation maintenance and the 
degradation of improperly folded and potentially harmful proteins. Referred to as the 
proteostasis network (PN), it consists of proteins termed molecular chaperones, which through 
their actions maintain protein homeostasis (proteostasis) in the cell32,33. Given that incorrect 
folding, aggregation and failed degradation of aggregates are characteristics of several NDs, 
chaperones of the PN have been suggested as modulators of pathogenic pathways in PD33. 
Indeed, molecular chaperones like heat-shock protein 70 and DJ-1 have been shown to interfere 
with or inhibit the aS aggregation process both in vitro and in cellular models34,35. As a result 
of these discoveries and the general importance of the PN, several chaperones are now being 
explored as potential modulators of aS aggregation and pathogenic PD pathways. Amongst 
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these proteins are the chaperone-like 14-3-3 family of scaffold proteins, which possess 
important roles in a great number of cellular processes36.   
 
1.6 THE UBIQUITOUS 14-3-3 PROTEINS  
 
Expressed in all eukaryotic organisms, 14-3-3 proteins are a highly conserved family of 
molecular scaffold and adaptor proteins involved in mediating signal transduction36. Through 
their interactions with a wide range of protein partners, these phospho-serine/threonine binding 
proteins take part in cellular processes such as cell proliferation, growth and apoptosis and 
intracellular protein trafficking37. Because of their important cellular roles, evidence implies 
dysfunctional regulation of 14-3-3 proteins as a contributor to many human diseases like cancer 
and NDs38. 
 
1.6.1 Structural Aspects 
 
The 14-3-3 family consists of several isoforms of ~30 kDa proteins. While the number of 
isoforms differs between species, they all share high sequence homology and a conserved 
structure38. With regards to the human proteins there are seven different isoforms (b, e, h, g, q, 
z and s), which have all been revealed to exist as homo- or heterodimers with a clamp-like 
structure (Figure 1.5)39,40. Each monomer comprises nine a-helices in an antiparallel 
arrangement, where the N-terminal regions associate to form a dimer interface mainly driven 
by hydrophobic and electrostatic interactions38,39. The monomers contain charged residues Lys, 
Arg and Tyr in helices a3 and a5, as well as hydrophobic Val and Ile/Leu residues in helices 
a7 and a941. Together, these residues form the amphipathic groove in which ligand binding 
occurs (Figure 1.5)42. Furthermore, the positioning of these grooves in the dimer allows for 
simultaneous binding of two peptides, whether they are in the same protein or two different 
target proteins41. However, only phosphorylated proteins containing specific phospho-serine 
motifs can bind to this groove. 14-3-3 proteins have been shown to specifically recognize three 
consensus phospho-peptide sequences: motif I (RSXpSXP), motif II (RX(Y/F)XpSXP) and 
motif III (pSX1–2–COOH)36,43, where pS represent phosphorylated Ser (or Thr) residues, and X 




Figure 1.5 – General structure of 14-3-3 protein bound to a phospho-peptide through its canonical binding 
mode. Proteins in the 14-3-3 family generally exist as homo-or hetero dimers, comprised of ~30 kDa 
monomers in a clamp-like structure39. Charged and hydrophobic residues within helices a3,5,7 and 9 form 
one amphipathic binding groove for each monomer, positioned to allow for binding of two phospho-peptides 
or one ligand with two phosphorylation sites41. Displayed in the figure is the crystal structure of 14-3-3g in 
complex with phosphoserine peptides. Retrieved from RCSB PDB: 2B05.  
 
1.6.2 Binding partners and cellular functions 
 
Because the motifs mentioned in Section 1.6.1 are present in a variety of proteins, 14-3-3 
proteins associate with a wide range of targets such as kinases and phosphatases, 
transmembrane receptors, transcription factors and other signaling molecules38. Indeed, more 
than 700 phosphoproteins are identified as possible targets of the 14-3-3 family in humans. 
Examples include Raf, BAD and Cdc25, which are all important signaling proteins bound by 
and regulated by different 14-3-3 isoforms40,41. The functions of 14-3-3s are thought to be 
carried out through one of three modes of action: (i) inducing a conformational change in the 
target protein, stabilizing its structure or accommodating it into the binding groove, (ii) 
interfering with protein-protein interactions by binding and preventing specific target protein 
regions from other interactions, or (iii) facilitate interaction between two target proteins by 
bringing them in close proximity, thus acting as an adaptor protein (Figure 1.6)38. Interestingly, 
some proteins display an isoform-specific affinity towards 14-3-3 proteins. The specific dimer 




Figure 1.6 – Ligand binding and adaptor function of proteins in the 14-3-3 family. The dimeric structure 
of 14-3-3 proteins allows simultaneous binding of two phospho-serine motifs, by accommodation into the 
binding grooves41. Through this canonical binding mode, 14-3-3 proteins perform a variety of regulatory 
functions in the cell. This occurs through the binding of a single protein (top panel) to induce a conformational 
change, stabilize its structure or shielding it from specific protein-protein interactions, or by bringing two 
proteins in close proximity (bottom panel) in order to facilitate their interactions38. Figure created in 
BioRender.com, and adapted from Cau et al38.  
 
In addition to their regulatory functions as adaptor/scaffold proteins, 14-3-3 proteins possess a 
molecular chaperone activity in protein quality control, preventing misfolding or unfolding 
proteins from aggregating44. Upon certain cellular stress conditions, 14-3-3 proteins can interact 
with unfolded or misfolded proteins to prevent their aggregation or assist in their proteolytic 
degradation41. If this should fail, 14-3-3 proteins have also been shown to mediate the formation 
of aggresomes, where protein aggregates are deposited to mitigate their toxicity and facilitate 
macroautophagic removal39. However, their chaperone activities are poorly understood, as they 
seem to be independent of substrate phosphorylation, thus occurring through mechanisms 
distinct from their canonical phospho-peptide binding mode41. Furthermore, several studies 
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suggest that monomeric forms of 14-3-3 display a more efficient chaperone activity, possibly 
due to the exposure of hydrophobic regions normally buried in the dimer interface44,45. 
However, further investigations are required to fully understand these mechanisms. Altogether, 
their many targets and different functions enable 14-3-3 proteins to be an integral part of a 
multitude of cellular processes like intracellular signaling, intracellular trafficking, 
transcription, apoptosis, cell cycle regulation and protein quality control37.   
 
1.6.3 14-3-3 Proteins in neurodegenerative disease  
 
As a result of the variety of important cellular processes they regulate, the 14-3-3 family has 
been implicated in several human diseases. They are abundantly expressed in the human brain, 
where they constitute approximately 1% of the soluble protein content and partake in neuronal 
differentiation and survival, regulation of ion channels, neuronal transmission and synapse 
plasticity38, much like the suggested functions of aS. In light of this and their established 
chaperone activity, 14-3-3 proteins are found to be involved in several NDs, including AD, CJD 
and PD38,46. Furthermore, isoform-specific 14-3-3 knockout studies in mice have resulted in 
certain syndrome phenotypes and revealed specific 14-3-3 isoform brain functions47. Moreover, 
14-3-3 isoforms b, e, h and g are found in the cerebrospinal fluid (CSF) of patients with CJD, 
and 14-3-3h was also found in the CSF from patients with other types of dementia such as 
AD48. Further supporting their involvement in neurodegeneration is the presence of 14-3-3 
proteins in LBs and neurofibrillary tangles characteristic of PD and AD brain sections, 
respectively47,49. Importantly, several isoforms are also able to interact with specific proteins 
involved in the pathogenesis of AD, ALS and PD47. With regards to PD, certain isoforms can 
interact with aS and other PD-related proteins like Parkin, Tyrosine hydroxylase and LRRK238. 
In particular, the 14-3-3h isoform appears to interact with and affect aS in its aggregation 
process9.  
 
1.7 AN ISOFORM OF INTEREST – 14-3-3h  
 
With a size of 28 kDa, 14-3-3h is a 14-3-3 isoform found in the cytosol or the extracellular 
environment of cells in various tissues. Like its protein family members, 14-3-3h adopts a 
homodimer conformation, is abundant in the human brain and possesses chaperone activity38,50. 
In NDs, this isoform is particularly interesting with regards to PD due to its association with 
aS and its effects on the aggregation process38.  
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1.7.1 14-3-3h and its interactions with a-Synuclein    
 
Unlike certain other 14-3-3h isoforms, immunostaining studies have not detected 14-3-3h in 
LBs of PD patients49,51. However, there are other indications that this isoform interacts with aS 
and is involved in the pathogenesis of PD. 14-3-3h was found to co-immunoprecipitate with 
aS from the substantia nigra of PD brains52, indicating an association between the two proteins 
in the affected brain region. Furthermore, in vitro experiments with aS and 14-3-3h 
demonstrated that 14-3-3h associates with aS and forms tight complexes termed non-fibrillar 
products (NFPs)9, a further indication that the two proteins interact (Figure 1.7). It is not yet 
clear as to which aS aggregation stage 14-3-3h binds, nor have the properties of a possible 
binding been reported. However, it has been suggested that 14-3-3h binds specifically to 
soluble aS oligomers9. Similarly, the binding mode through which 14-3-3h binds aS has yet 
to be characterized. The interaction does not appear to follow the canonical phospho-peptide 
binding mode, as 14-3-3h have been shown to interact with unphosphorylated aS9. Moreover, 
14-3-3h, like all isoforms of the 14-3-3 family, also displays chaperone activity where the mode 
of binding is less characterized44. Taken together, these findings suggest an interaction between 




Figure 1.7 – TEM images of aggregated a-Synuclein (aS) fibrils and a-S/14-3-3h complexes. 
Experimental work by Plotegher et al9 shows TEM images of mature aS fibrils obtained by aggregating aS 
alone (A), compared to the smaller, non-fibrillar products (NFPs) obtained by aggregating aS in the presence 
of 14-3-3h in a 4:1 ratio (B). Interaction with 14-3-3h during the aggregation process thus affects the aS 
aggregation pathway, rerouting it towards the smaller NFPs rather than mature fibrils. Figure from Plotegher 
et al9.  
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1.7.2 The role of 14-3-3h in a-Synuclein aggregation and Parkinson’s disease pathology  
 
With regards to the aS aggregation process, in vitro fluorescence-monitored studies by 
Plotegher et al9 showed that 14-3-3h was able to attenuate aS aggregation by reducing fibril 
formation, even when present in sub-stochiometric amounts of 4:1 (aS:14-3-3h). This study 
also implied that 14-3-3h interacts with oligomeric species of aS rather than monomers, leading 
to the formation of NFPs (Section 1.7.1) rather than canonical aS fibrils9. Hence, this points to 
a suppressing and neuroprotective role of 14-3-3h in fibril formation. Furthermore, these 
observations appeared to be isoform-specific to 14-3-3h. However, the suppressing effects of 
14-3-3h ceased at a critical aS:14-3-3h ratio or when aS aggregation had already progressed 
to the later stages. In these conditions, 14-3-3h becomes sequestered into aS fibrils and are no 
longer able to affect the process9. Moreover, 14-3-3h is connected to PD in other aspects as 
well. Sato et al52 showed that 14-3-3h binds to and regulates the activity of Parkin, a ubiquitin 
ligase which if mutated leads to early onset PD and is suggested to interact with aS53. Hence, 
overexpression of aS and its progressing aggregation could sequester 14-3-3h from the 
Parkin/14-3-3h complex, depriving the cells of regulatory processes. Interestingly, 
overexpressing 14-3-3h reduced aS-induced cellular toxicity in HEK293 cells overexpressing 
aS9. In summary, 14-3-3h could be a protein of interest in uncovering suppressors of aS 
aggregation and therapeutic targets in PD.  
 
1.8 BIOPHYSICAL METHODS FOR STUDYING PROTEINS IN VITRO  
 
In this thesis, several methods were employed to investigate protein interactions, structure and 
aggregation kinetics. Common to all these methods is their basis in biophysics. This section 
provides an overview of two key methods and their underlying principles.  
 
1.8.1 Thioflavin T (ThT) monitored aggregation assays 
 
Studies of aggregating proteins such as αS are often conducted in vitro, as a convenient means 
to investigate both aggregation kinetics and influencing factors. Such aggregation assays are 
commonly performed with the fluorescent dye named Thioflavin T (ThT)54. When existing 
freely in solution, ThT rotates around a central C–C bond, and exhibits weak fluorescent signals 
only when it enters a certain rotational position. Upon binding to the cross-β structure of 
amyloid fibrils however, this bond is immobilized. As a result, ThT becomes sterically locked 
in a position that emits a strong fluorescent signal with excitation and emission maxima at 450 
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nm and 480 nm, respectively55. ThT is thus a sensitive reporter of amyloid fibril formation and 
can be used to monitor aS fibril formation in vitro. ThT-monitored aggregation assays are 
normally performed in fluorescence plate-reader format, e.g. in a 384-well microplate, which 
allows multiple samples and conditions to be tested simultaneously (Figure 1.8)54. Protein 
samples with ThT, and possibly influencing factors, can then be exposed to aggregation-
promoting conditions and monitored by measuring the fluorescence intensity of ThT over time. 
This yields a fluorescence curve whose intensity is proportional to the fibril formation over 
time, providing a starting point for assessing the kinetics of protein aggregation. However, fibril 
nucleation and growth are rather stochastic in nature. Consequently, these types of assays 
usually require multiple replicates and can be prone to poor reproducibility54.    
 
 
Figure 1.8 – ThT-monitored aggregation assays: experimental overview. Multiple samples of an amyloid 
protein mixed with ThT, and possibly aggregation-influencing factors, are pipetted into a microplate with 
several wells. A fluorescence microplate-reader set to aggregation-promoting conditions is then used to 
measure ThT fluorescence in the samples over time. Due to the fibril-dependent ThT-fluorescence, this yields 
a fluorescence curve which is proportional to the number of fibrils; the intensity increases as the aggregation 
process transitions from primary nucleation to fibril elongation and finally the plateau phase of fibrils only. 
Figure created in BioRender.com.  
 
1.8.2 Nuclear magnetic resonance (NMR) spectroscopy 
 
When subjected to a strong magnetic field and electromagnetic pulse, NMR active nuclei 1H, 
13C and 15N emit resonance signals of varying frequencies as they transition between energy 
levels. These signal frequencies are Fourier-transformed to chemical shifts (δ [ppm]), which 
differ between the nuclei depending on the atoms surrounding them, i.e. their position in a 
molecule. These signals can then be detected and processed into spectra which give information 
about protein structure56. Moreover, nuclei linked either through-bond or through-space can 
exchange excitation energy, yielding correlated signals termed cross-peaks. In protein 
biochemistry, this has proven incredibly useful. Depending on the type of experiment and the 
isotope-labeling of a protein, two-dimensional (2D) or three-dimensional (3D) spectra can be 
acquired from a protein sample. Subsequently, the cross-peaks of specific δ-values can be 
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exploited to determine structural information about the protein, such as size, backbone residues, 
information about neighboring residues and indications of the protein fold57. As an example, 
1H-15N heteronuclear single quantum coherence spectroscopy (HSQC) can be used to detect N-
H bonds in the backbone peptide bonds. Therefore, NMR spectroscopy has become an 
integrated part of structural molecular biology and can even be employed when investigating 
protein-protein interactions56. However, NMR spectroscopy has its limitations; structures of 
large proteins are still challenging to solve, due to their great number of nuclei and fast 
relaxation rates creating complex spectra58. With more recently developed techniques such as 
transverse relaxation optimized spectroscopy (TROSY), this size limit has greatly increased58 
but remains a challenge.   
  
1.9 AIMS AND OBJECTIVES OF THE STUDY   
 
To this day, there is no early diagnostic method nor effective treatments for PD7,8. However, 
fibrillar products of aS have been discovered as the primary component of LBs; insoluble 
inclusions found in parkinsonian brains9,10. The misfolding and aggregation of this small 
synaptic protein is therefore deemed of great importance in the PD pathogenesis. Several 
proteins are now evaluated and researched as potential suppressors of these mechanisms. In this 
context, the 14-3-3 family of chaperone-like proteins have received attention in the search for 
neuroprotective factors and possible therapeutic targets9,47. In particular, the 14-3-3h isoform 
shows promise as a modulator of aS aggregation, and a possible rescuer of aS-induced cellular 
toxicity9. Uncovering the role of 14-3-3 proteins in PD could therefore be important in 
understanding the disease pathogenesis and in the search for therapeutic targets. In this study, 
we aim to elucidate the effects of 14-3-3h on PD-related aS aggregation and characterize the 
interaction between the two proteins based on the following hypotheses:  
 
1. The presence of 14-3-3h influences aS aggregation kinetics and could be part of a 
proteostasis network which counteracts aggregation processes harmful to cells.  
2. 14-3-3h interacts with aS only at certain aggregation states through a non-canonical 
binding mode for 14-3-3 proteins. 
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2. MATERIALS   
 
2.1 CHEMICALS  
 
Table 2.1: Chemicals and reagents used in various experiments 
Chemical Formula Supplier  #Cat. Number 
10 % Ammonium Persulfate  APS Sigma - 
Ampicillin Sodium Salt  Ampicillin Sigma A0166 
Benzamidine - Sigma B-6506 
Chloramphenicol C11H12Cl2N2O5 Sigma C0378 
cOmplete, EDTA-free: protease 






DL-dithiothreitol DTT Merck D9163 
Ethylenedinitrilotetraacetic acid  EDTA Merck 1.08418.1000 
Glucose  C6H12O6 Sigma  49159 
Glutathione  - Sigma G4251 
Glycine  C2H5NO2 Sigma G8898 
Hydrochloric acid HCl - - 
Imidazole  C3H4N2 Sigma 792527 
Isopropyl 1-thio-β-D-
galactopyranoside  
IPTG Sigma I5502 
Lysogeny Broth-Agar   LB-Agar Sigma  L2897 
Magnesium Chloride MgCl2 • 6H2O Merck  1.05833.1000 
Magnesium Sulfate MgSO4 Sigma-Aldrich M-7506 
Peptone (Tryptone) - Merck 1.07213.1000 
Potassium Chloride  KCl Merck 1.04936.1000 
Saccharose C12H22O11 Sigma S9378 
Sodium Azide  NaN3 - - 
Sodium Chloride  NaCl VWR Chemicals 27810.295 
Sodium dihydrogen phosphate, 
monobasic 
NaH2PO4 • H2O Sigma 71662 
Sodium hydrogen phosphate, 
dibasic 
Na2HPO4 • 2H2O Sigma 71504 
20% Sodium Dodecyl Sulfate SDS Alfa Aesar J63394 
Sodium Oxide NaOH - - 
N,N,N',N'-tetramethylethane-
1,2-diamine 
TEMED Sigma T9281 
Thioflavin T  ThT Sigma T3516 
TPE-TPP - - - 
Trizma Base Tris Sigma T1503 
Yeast Extract  
(granulated) 




2.2 ISOTOPES   
 
 
Table 2.2: Isotopes used for labeled protein expression 
Isotope Formula Supplier #Cat. Number 
13C D- glucose  13C6H12O6 Cambridge Isotope 
Laboratories 
CLM-1396-1 
15N-ammonium chloride 15NH4Cl Sigma 299251 
Deuterium Oxide  D2O Cortecnet D214K 
 
 
2.3 PLASMIDS AND PRIMERS   
 
Table 2.3a: Plasmids used for sequencing and expression 
Plasmid  Supplier  #Cat. Number 
pET21a-a-Synuclein AddGene 51486 
pGEX-2T-14-3-3h Kind gift from Dr. Rune Kleppe  - 
 
Table 2.3b: Primers used for sequencing 
Primer Sequence (5’ - 3’) Supplier 
pGEX 2TSeq  ATATAGCATGGCCTTTGCAG Sigma 
T7 Terminal primer  GCTAGTTATTGCTCAGCGG Addgene 
 
 
2.4 ENZYMES, PROTEINS AND CELLS  
 
Table 2.4: Enzymes, proteins and cells  
Name  Application  Supplier  
Benzonase Nuclease Cell lysis  Sigma 
BL21 Starä (DE3) Chemically 
Competent E. coli 
 
Protein Expression  ThermoFisher Scientific 
Bovine Serum Albumin (BSA) Aggregation assays Sigma  
Bovine Serum Albumin (BSA), 
fatty acid (FA)-free 
Aggregation assays Sigma 
Lysozyme from chicken 
 
Cell lysis Sigma 
Thrombin  14-3-3h cleavage - 
Tobacco Etch Virus (TEV) 
Enzyme   




2.5 COMMERCIAL REAGENTS, MATERIALS AND KITS 
  
Table 2.5: Commercial reagents and materials  
Material   Application  Supplier  
10X HBS-EP+ buffer SPR interaction studies GE Healthcare 
384-well black microplate, 
clear bottom 
  
Aggregation assays Corning  
Acrylamide-Bisacrylamide 
30% 37.5:1 
SDS-PAGE Sigma  
Amicon 10 kDa 
Centrifugation filter  
Up-concentrating proteins Millipore 







Protein purification GE Healtchare 
HiLoad 16/600 Superdex 75 
pg 
Protein Purification  GE Healthcare 
HiTrap Hp 5mL Protein purification  GE Healthcare 
Immobilization buffer 
(Acetate buffer) pH 4.0 
SPR interaction studies GE Healthcare 
Instant Blueä Protein Stain Visualization of proteins Expedeon 
Precision Plus Protein  
DualColor Standard 
Protein marker  Bio-Rad  
 
 
2.6 INSTRUMENTS AND EQUIPMENT  
 
Table 2.6: Instruments and equipment  
Instrument    Application  Manufacturer   
AEKTA Explorer  Protein purification GE Healthcare 
Biacore T200 SPR interaction studies GE Healthcare 
Bruker Advanced  NMR Experiments Bruker  
FLUOStar Optima Aggregation assays BMG Labtech 
GelDocä XR+ Gel Imaging  Bio-Rad  
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2.7 COMPUTER SOFTWARE  
 
Table 2.7: Computer software and web resources  
Software    Application  Manufacturer   
MatLab R2018b Processing fibrillation curves MathWorks 
TopSpin 4.0.7 Processing NMR spectra Bruker 
Pint Analyzing NMR spectra Pint 
Biacore Evaluation Software Evaluating SPR results GE Healthcare 
ImageLab 5.2.1 Processing Gel images BioRad 
BioRender.com Creating figures BioRender 
 
 
2.8 BUFFERS, MEDIA AND SOLUTIONS  
 
MilliQ Ultrapure water was used in all buffers and solutions unless otherwise stated. 
 
2.8.1 Buffers and solutions for protein expression  
 
LB-agar   Lysogeny broth (LB) medium 
37 g/L LB-Agar Broth   10 g/L Peptone (Tryptone) 
5 g/L Yeast Extract (granulated) 
10 g/L NaCl 
 
Ampicillin stock solution Chloramphenicol stock solution 
100 mg/ml Ampicillin Sodium Salt 34 mg/ml Chloramphenicol  
(Dissolved in 70% ethanol)   
 
IPTG stock solution SOC medium 
1M IPTG  0.5 % Yeast Extract 
2 % Tryptone 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM Glucose  
 
 
2.8.2 Buffers and solutions for isotope-labeled protein expression  
 
5X M9 Salts (filtered) 5X M9 Salts Wash (filtered) 
110 mM KH2PO4 
240 mM Na2HPO4  
2.5 g/L NaCl 
5 g/L 15NH4CL 
110 mM KH2PO4 
240 mM Na2HPO4 




1L 5M Modified minimal medium (filtered)  
200 mL 5XM9 Salts 
4 g D-Glucose 13C  
2.5 mL 100X BME Vitamins 
2.0 mL 1M MgSO4 
1 mL/L Trace Metal Solution  




2.8.3 Buffers and solutions for protein purification  
 
Osmotic shock buffer HisTrap wash buffer (filtered) 
30 mM Tris-HCl pH 8 
40% w/v Saccharose  
2 mM EDTA 
 
20 mM Tris-HCl pH 8.0 
150 mM NaCl 
20 mM Imidazole 
 
10 X PBS pH 7.3 (filtered) HisTrap elution buffer (filtered) 
100 mM Na2HPO4 • 2H2O 
18 mM KH2PO4  
1.4 M NaCl 
27 mM KCl 
 
20 mM Tris-HCl pH 8.0 
150 mM NaCl 
500 mM Imidazole 
Cell lysis Buffer TEV cleavage buffer  
1 X PBS  
1 mM EDTA 
1 mM DTT 
1/50 mL EDTA-free protease inhibitor 
tablets 
10 mM Benzamidine 
1U/ml Benzonase 
0.5 mg/ml Lysozyme  
 
20 mM Tris-HCl pH 8 
150 mM NaCl 
0.5 mM EDTA 
1 mM DTT 
 
1 M Sodium phosphate buffer pH 7.4 1 M sodium phosphate buffer pH 6.0  
0.612 M Na2HPO4 • 2H2O 
0.388 M NaH2PO4 • H2O 
 
0.13 M Na2HPO4 • 2H2O 
0.87 M NaH2PO4 • H2O 
 
GST elution buffer  
50 mM Tris-HCl pH 8.0 
20 mM Glutathione  











SDS-PAGE electrophoresis buffer pH 8.3 4X SDS Sample buffer 
192 mM Glycine 
25 mM Tris 
0.1 % w/v SDS  
 
200 mM Tris HCl pH 6.8 
17% Glycerol  
4% SDS  
10% b-mercaptoethanol 
0.005% Bromophenol blue 
0.0005 % Pyronin B  
 
2 x 0.75 mm 4% SDS-PAGE stacking gel  2 x 0.75 mm 13% SDS-PAGE resolving gel  
125 mM Tris-Glycine pH 6.8  
4% Acrylamide-Bisacrylamide  
0.1% SDS  
0.05% APS  
0.1% TEMED  
 
375 mM Tris-Glycine pH 8.8  
13% Acrylamide-Bisacrylamide  
0.1% SDS 
0.05% APS  
0.05% TEMED  
 
 
2.8.5 Buffers for nuclear magnetic resonance spectroscopy  
 
 
NMR buffer pH 6.0 NMR buffer pH 6.8 
20 mM sodium phosphate pH 6.0  
100 mM NaCl 
0.02% w/v NaN3 
 
20 mM sodium phosphate pH 6.8  
100 mM NaCl 
0.02% w/v NaN3 
 
NMR buffer pH 7.4   
20 mM sodium phosphate pH 7.4  
100 mM NaCl 





2.8.6 Thioflavin T (ThT) monitored a-Synuclein aggregation assays  
 
 
PB buffer no salt  PB buffer w/salt  
20 mM sodium phosphate pH 6.0 
1 mM EDTA  
0.02% NaN3 
20 mM sodium phosphate pH 6.0 
1 M NaCl  
1 mM EDTA  
0.02% NaN3 
 
ThT Pre-stock Solution   ThT Stock Solution (filtered) 
8.5 M ThT  1 mM ThT  
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3. METHODS   
 
The primary goal of this thesis was to employ ThT-monitored aggregation assays to investigate 
how 14-3-3h affects the kinetics of aS aggregation in vitro, and further characterize the binding 
between 14-3-3h and aS by NMR spectroscopy and surface plasmon resonance (SPR) 
experiments.  
 
3.1 a-SYNUCLEIN EXPRESSION AND PURIFICATION 
 
3.1.1 a-Synuclein expression  
 
Sequencing of the pET21a-a-synuclein plasmid was performed to check for plasmid mutations 
that may affect the translated protein, following the BigDye v.3.1 Protocol. E. coli BL21 (DE3) 
Star chemically competent cells were incubated 15 min on ice, then transformed with 6xHis-
tagged pET21a-a-synuclein (Addgene) with a TEV cleavage site. After additional 30 min ice 
incubation, heat-shock was applied for 30 sec at 42°C to enable uptake of plasmid DNA, 
followed by 2 min ice incubation before the cells recovered in 250 µl SOC medium. Bacterial 
colonies grew overnight on LB-Agar plates w/Ampicillin (100 µg/ml), and a single colony was 
used to inoculate a starter-culture of LB medium. Bacterial growth occurred in 4 L LB-medium 
w/Ampicillin (100 µg/ml) at 37°C and 250 rpm until OD = 0.4, upon which aS expression was 
induced by addition of 0.1 mM IPTG. The protein was expressed in culture for 5 hours (37°C 
and 250 rpm).   
 
3.1.2 Extraction of periplasmic content  
 
Bacteria were harvested by centrifugation (15 000 g, 4°C, 20 min), and the cell pellet 
resuspended in Osmotic shock buffer (250 mL/L of original culture). Subsequently, the 
resuspension was incubated at room temperature (10 min) before harvest by centrifugation 
(15 000 g, 4°C, 20 min) to obtain a new pellet of 4X concentrated cells. This pellet was 
resuspended in cold 1mM MgCl2 before the periplasmic content (PC) was recovered by 
centrifugation (15 000 g, 4°C, 20 min) as a supernatant. To inhibit proteolytic cleavage, 20 mM 
sodium phosphate buffer pH 7.4 w/EDTA-free protease inhibitors was added to PC prior to 
further purification. 
 
3.1.3 Chromatography purification  
 
Exploiting the affinity of the 6xHis-tag imidazole rings to Ni2+ ions, aS was purified from the 
PC by HisTrap affinity chromatography (AEKTA Explorer system, GE Healthcare), using 
 29 
HiTrap HP 5mL columns. Non-specific proteins were eluted with HisTrap wash buffer before 
elution of aS was induced by increasing concentrations of HisTrap elution buffer (flowrate 0.5 
ml/min), while monitoring protein fractions with UV280 absorbance. Subsequently, the aS 
buffer was exchanged to TEV Cleavage buffer (20 mM Tris-HCl pH 8, 150 mM NaCl,0.5 mM 
EDTA,1 mM DTT) using PD10 columns, before overnight cleavage at 4°C with 1mg/50mgaS 
of TEV (purified locally) to remove the His-tags. A second affinity chromatography was used 
to purify cleaved aS as column flow-through. Eluted protein was concentrated with a 10 kDa 
spin column (Amicon Ultra, Millipore). aS was further purified by running size-exclusion 
chromatography (SEC, AEKTA Explorer system), using the HiLoad Superdex 75 pg 16/600 
column with 20 mM sodium phosphate pH 6.0 w/ 100 mM NaCl (flowrate 1.0 ml/min). Purified 
aS was stored at -80°C until use.  
 
3.2 14-3-3h EXPRESSION AND PURIFICATION  
 
3.2.1 14-3-3h Expression 
 
Sequencing of the expression vector pGEX-2T-14-3-3h was performed to check for mutations 
that may affect the translated protein, following the BigDye v.3.1 Protocol. E. coli BL21 (DE3) 
Star chemically competent cells were transformed with GST-tagged pGEX-2T-14-3-3h with a 
Thrombin cleavage site, by the procedure described in Section 3.1.1. Colonies grew overnight 
in LB-Agar plates w/Ampicillin (50 µg/ml) and Chloramphenicol (34 µg/ml), and a starter-
culture was inoculated with a single colony. Growth occurred in 2L LB-medium w/Ampicillin 
(100 µg/ml) and Chloramphenicol (34 µg/ml) at 37°C and 250 rpm, and protein expression was 
induced with 1 mM IPTG at OD=0.8. Based on testing of various expression conditions, 14-3-
3h was expressed in culture at 25°C and 250 rpm overnight to achieve optimal yield.  
 
3.2.2 Cell lysis  
 
Bacteria were harvested by centrifugation (15 000 g, 4°C, 20 min) and the cell pellet 
resuspended in Cell lysis buffer (1 X PBS, 1 mM EDTA, 1 mM DTT, 1/50 mL EDTA-free 
protease inhibitors, 10 mM Benzamidine, 1U/ml Benzonase, 0.5 mg/ml Lysozyme). Cells were 
then lysed by sonication (50% amplitude, 30 sec on/15sec off, 10 min), centrifuged (15 000 g, 
4°C, 20 min) and the cell lysate (CL) collected in the supernatant.  
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3.2.3 Chromatography purification  
 
GST-tagged 14-3-3h was purified from CL by GST-Glutathione affinity chromatography using 
a Glutathione-Sepharose resin (6 ml). The column was equilibrated with three column volumes 
(CV) of 1XPBS w/protease inhibitors (10 mM Benzamidine and 1 EDTA-free protease 
inhibitor tablet), before CL was added on the glutathione resin and incubated at for 30 min at 
4°C. The lysate/resin was washed with 3 CV of 1XPBS w/protease inhibitors to remove 
unspecific proteins. Subsequently, the column was washed with 3 CV of 1XPBS and 
resuspended in 1 CV 10 U/ml Thrombin in 1XPBS (expressed locally) for incubation overnight 
(4°C, w/shaking) to remove the GST tag. 14-3-3h was eluted with 1XPBS and collected in 0.5-
1.5 ml fractions, and the column was equilibrated with GST Elution buffer and 20% ethanol. 
Fractions of 14-3-3h with Absorbance280 > 0.5 were pooled and up-concentrated in a 10 kDa 
Spin Column (Amicon Ultra, Millipore). SEC was performed as the final purification step on 
the HiLoad Superdex 75 pg 16/600 column as described in Section 3.1.3, and the protein was 
stored at -80°C until use.  
 
3.3 EXPRESSION OF ISOTOPE-LABELED a-SYNUCLEIN AND 14-3-3h  
 
E. coli BL21 (DE3) Star chemically competent cells were transformed with pET21a-a-
synuclein and pGEX-2T-14-3-3h and cells grown in 4L LB medium as described in Sections 
3.1.1 and 3.2.1 until OD=0.4 and 0.8. Cells were harvested by centrifugation (15 000 g, 4°, 20 
min) and resuspended in 5X M9 Salts Wash (250 ml/L original culture) before a second 
centrifugation (15 000 g, 4°C, 20 min) to obtain a 4X concentrated cell pellet. The 4X 
concentrated cells were then resuspended in 1L 5 M Modified minimal medium containing 15N-
ammonium chloride and 13C-glucose (and D2O for triple-labeled expression), then incubated at 
37°C, 250 rpm for one hour. Subsequently, expression of the isotope-labeled proteins was 
induced as in Sections 3.1.1 and 3.2.1. Purification was performed as in Sections 3.1.3 and 
3.2.3.  
 
3.4 SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS 
 
To evaluate the degree of protein purity, samples from the purification processes (Sections 3.1, 
3.2, 3.3) were analyzed by sodium dodecyl sulphate- polyacrylamide gel electrophoresis (SDS-
PAGE). Samples were prepared by adding 1X SDS sample buffer followed by incubation at 
95°C for 5 min to achieve protein denaturation. In volumes ranging from 3-20 µL, samples 
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were loaded on a 13 % polyacrylamide gel (4 % stacking gel), using Precision Plus Protein 
Standardä DualColor (BioRad) as size marker. Electrophoresis ran at 80-120 V until 
satisfactory separation was obtained. Proteins were subsequently stained with Instant Blueä 
Protein Stain (Expedeon) for 15 min and visualized with GelDocä XR+ (BioRad).  
 
3.5 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY  
 
3.5.1 Sample preparation   
 
Three 180 µM 13C15N-labeled aS samples were prepared in NMR buffer (20 mM sodium 
phosphate, 100 mM NaCl, 0.02% NaN3) with pH 6.0, 6.8 and 7.4, supplemented with 5% D2O 
and pipetted into NMR tubes in volumes of 300 µL. One sample of 264 µM 13C15N-labeled 14-
3-3h was prepared in NMR buffer pH 6.0, supplemented with 5% D2O before 300 µL was 
pipetted into the NMR tube. One sample of approximately 50 µM 2H13C15N-labeled 14-3-3h 
was prepared in NMR buffer pH 6.0, supplemented with 5% D2O before 500 µL was pipetted 
into the NMR tube.    
 
3.5.2 Acquisition and Processing  
 
Data were collected at 25°C on an 850 MHz Bruker Advanced III HD Spectrometer fitted with 
a 1H13C15N TCI CryoProbe and a SampleJet with temperature control for storing samples 
between runs (set to 4°C). Prior to data acquisition, the instrument was locked onto D2O in the 
sample, tuned and matched. Samples were shimmed using the automated gradient shimming 
protocol “TopShim”, while probe- and solvent specific parameters were set with the “getprosol” 
command. Gradients were set with the “gppp” command. For 2D experiments, only the number 
of scans (ns) and the number of transients in the artificial time domain(s) (TD1, TD2) were 
typically adjusted. Datasets were processed into the final spectra in TopSpin 4.0.7. Linear 
prediction up to twice the number of acquired points were performed in the artificial time 
domains to improve resolution. Datasets were processed using square cosine functions for 




3.5.3 NMR Experiments 
 



















1H15N-HSQC hsqcetf3gpsi 7.9911, 35.0001 2048, 256 10 180 µM 
13C15N-aS 
1H15N-HSQC hsqcetf3gpsi 7.9911, 35.0001 2048, 256 10 264 µM 
13C15N-  
14-3-3h 





trosyetf3gpsi 17.9312, 35.0000 2048, 128 224 
 
 
3.6 THT-MONITORED a-SYNUCLEIN AGGREGATION ASSAYS  
 
The b-sheet fibril-dependent fluorescence of ThT was used to monitor aS aggregation in the 
absence and presence of 14-3-3h. All fluorescence readings were performed with FLUOStar 
Optima Microplate Fluorescence Reader, using a black 384-well polystyrene microplate with 
clear bottom, sealed with sealing tape to avoid evaporation of samples. Excitation and emission 
wavelengths were set to 430 nm and 485 nm for ThT, and the fluorescence gain was set to 20%.   
 
3.6.1 Optimizing salt concentrations  
 
To find the optimal buffer salt concentration, samples were prepared in PB buffer pH 6.0, with 
fixed concentrations of 5µM ThT, 60 µM aS and varying NaCl concentrations of 100, 200 and 
500 mM NaCl. Additionally, a ThT blank was prepared in PB buffer w/100 mM NaCl. The 
assay was performed with 20 wells/sample and 50 µL/well. At 37 °C, fluorescence was 
measured in time intervals of 700 s, with 300 s and 7 mm orbital shaking, for 140 hours.  
 
3.6.2 Investigating the influence of 14-3-3h on a-Synuclein aggregation  
 
Samples were prepared in PB buffer pH 6.0 with fixed concentrations of 200 mM NaCl, 5µM 
ThT, 100 µM aS and varying concentrations of 14-3-3h (0, 10, 20 and 55 µM). An additional 
sample with aS and 55 µM BSA or fatty acid-free (FA-free) BSA was prepared as controls. 
The assay was performed with 15 wells/sample and 50 µL/well. Fluorescence was measured at 
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37°C, in 700 s cycles with 300s and 2 mm orbital shaking, for 140 hours. Five independent 
replicates were performed with aS and 14-3-3h to achieve increased reliability of the results, 
but only three replicates with aS + BSA and aS + FA-free BSA could performed within the 
time restrictions of the project. The recorded fluorescence data were processed in MatLab 
R2018b, using an in-lab written script. The resulting fluorescence curves were fitted to the two-
step model in Equation 1, 2 to obtain lag times, tn, and rate constants, n, for aS aggregation. 
Additionally, they were further processed in a cumulative aggregation analysis, evaluating the 
percentage of wells with a signal above a threshold of three times higher than the noise. 
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3.7 SURFACE PLASMON RESONANCE (SPR) INTERACTION STUDIES 
 
By detecting small changes in the refractive index of thin films on sensor chips, SPR is used as 
a highly sensitive method for monitoring protein-protein interactions, and was therefore used 
to investigate the binding between 14-3-3h and aS. The method is based on the generation of 
a surface plasmon wave (a collection of conducting electrons), which changes the angle and 
intensity of reflected light, depending on the molecular mass of the sensor chip. An analyte 
protein binding to or dissociating from a ligand immobilized to the chip surface will change the 
surface molecular mass, and thus change the angle of reflected light. This change is detected in 
arbitrary response units (RU), used to evaluate the properties of the interaction59.  
 
Studies were performed with the BiaCore T200 instrument, in HBS-EP+ buffer (GE 
Healthcare). To investigate the binding of aS and 14-3-3h, aS was covalently linked by 
standard amine coupling to a CM5 sensor Chip. The flow cell system was primed with HBS-
EP+ buffer, then pre-conditioned with HBS-EP+, 100 mM HCl, 50 mM NaOH and 0.5 % SDS 
prior to activation with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-
hydroxysuccinimide (NHS). Monomeric aS (50 µg/ml), filtered to avoid oligomer 
contamination, was immobilized to the chip on flow path 2 via amino coupling, in 10 mM 
acetate buffer with pH adjusted to 3.7, to a final density of 1900 response units (RU). Flow 
paths 1 and 2 were then blocked with ethanolamine to prevent non-specific binding, leaving 
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flow path 1 as a reference. Non-specifically immobilized ligand was removed from the CM5 
chip by washing for several hours at 50 μl/min with HBS-EP+ running buffer prior to SPR 
analysis. Experiments were performed at 25 °C in running buffer at a flow rate of 25 μl/min. 
Subsequently, 14-3-3h in concentrations of 0.5, 1.0, 2.5, 5.0 and 10 µM was used for binding 
analysis, with 240 s contact time, 600 s dissociation time and a 30 s stabilization period. 10 mM 
Glycine pH 2.2 at 30 µl/min was used to regenerate the chip between each concentration. A 
blank run with HBS-EP+ buffer was subtracted from all curves after removing the signal from 
the reference cell. The resulting sensorgrams were evaluated in BiaCore evaluation software 





4. RESULTS   
 
4.1 PROTEIN EXPRESSION AND OPTIMIZATION 
 
4.1.1 a-Synuclein expression and purification  
 
To prepare protein material for use in aggregation experiments and interaction studies with 14-
3-3h, recombinant aS was overexpressed in E. coli and purified by two-step column 
chromatography. After expression and purification, pure protein was achieved in yields of 10-
12 mg from 4 L bacterial culture. The protein eluted as a single peak at a 60 ml elution volume, 
but with a shoulder towards higher elution volumes (Figure 4.1, a). aS is a small protein and 
was thus expected to elute at higher elution volumes, which could indicate that the presence of 
oligomers. However, aS has previously been found to migrate as a 57-60 kDa protein, rather 
than its actual size of 14 kDa, due to its intrinsically disordered and extended conformation.60 
It is therefore possible that the larger peak represents monomeric aS, and the shoulder towards 
higher elution volumes could represent a minor amount of oligomeric species, migrating as 
their actual size.  
 
After cleavage by TEV, the His-tag which enabled aS to bind the Ni2+ matrix was successfully 
removed, seen by the decrease in protein size from 16.8 kDa to 14.9 kDa (Figure 4.1, b), the 
latter corresponding to the size of monomeric aS. However, as oligomers would present as 
monomers in a denatured protein solution, oligomer contaminations could have been present. 
Furthermore, a clear increase in purity of aS was observed after the 2nd HisTrap 
chromatography, however, some minor contaminations were still present in the sample, as seen 
in the gel sample from the 2nd round of HisTrap purification (Figure 4.1, b). Therefore, a final 
polishing step of SEC proved necessary in order to achieve the desired purity, with aS displayed 




Figure 4.1 – Purification of recombinant a-Synuclein (aS). aS was expressed in E. coli BL21 (DE3) Star 
and purified by a two-step column chromatography, exploiting the affinity of a His-tag to a Ni2+ matrix, 
followed by subsequent SEC on the HiLoad Superdex 75 pg 16/600 column to achieve the highest possible 
purity. a) The SEC elution profile displayed one asymmetric peak, representing monomeric aS in the final 
sample. b) Samples from the purification process analyzed by SDS-PAGE revealed a clear increase in purity 
from the pellet of induced culture to the final purified product (circled), as well as a decrease in size from 
16.8 kDa to 14.9 kDa upon cleavage of the His-tag (red arrows).   
 
4.1.2 14-3-3h Expression and purification  
 
In order to perform binding and aggregation experiments investigating the effect of 14-3-3h on 
aS, a recombinant 14-3-3h expression system (a gift from Dr. Rune Kleppe) was established 
and optimized. The protein was overexpressed in E. coli using a pGEX-2T-14-3-3h expression 
vector and purified by GST-glutathione affinity chromatography. Three different expression 
conditions were tested to optimize the method: 37°C for 4 hours, 30°C for 4 hours and 25°C 
overnight. SDS-PAGE analysis of the induced cultures indicated no differences in protein yield, 
and expression at 25°C overnight was therefore deemed the most convenient. Further 
optimization of the purification procedure revealed that a Glutathione resin and manual 
monitoring of the chromatography was preferable to using the automated AEKTA Explorer 
system and pre-packed columns.  
 
Expression at 30°C for 4 hours and purification with the automated chromatography system 
yielded three peaks in the SEC elution profile (Figure 4.2, a), suggesting protein of lower purity, 
with contaminations corresponding to the size of GST (Figure 4.2, b). While keeping the same 
expression conditions and decreasing the flowrate of the automated chromatography system did 
improve purity, two peaks were still seen in the SEC elution profile (Figure 4.2, c). Expression 
at 25°C overnight and purification by automated chromatography with the decreased flow rates 
improved the purity to one elution peak (Figure 4.2, d), however, the protein yield was low. 
a) b) 
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Therefore, we opted to express 14-3-3h at 25°C overnight and purify the protein by manual 
chromatography with a glutathione resin to bind more protein to the column.  
 
 
Figure 4.2 – Optimization of 14-3-3h expression conditions and purification. 14-3-3h was overexpressed 
in E. coli BL21 (DE3) Star in various conditions and purified with the AEKTA Explorer system. a) 
Expression at 30°C for 4 hours and purification with AEKTA Explorer yielded three peaks in the elution 
profile. b) Analysis by SDS-PAGE revealed that contaminations were likely cleaved GST (--) eluted with 
14-3-3h (*). c) Expression at 30°C for 4 hours, and lowered flowrates in the AEKTA system improved purity, 
but still yielded two peaks in SEC elution profile. d) Expression at 25°C overnight and lowered flowrates 
yielded pure protein, but low yield.  
   
Using these methodological adaptations, GST-Glutathione chromatography and subsequent 
SEC yielded one peak in the SEC elution profile (Figure 4.3, a) and one 28 kDa protein band 
in SDS-PAGE analysis (Figure 4.3, b), indicating a high degree of 14-3-3h purity. Moreover, 
the protein eluted at a ~55 mL elution volume. Because this volume was expected for a protein 
twice the size of 14-3-3h monomers, this indicated that 14-3-3h was eluted in the dimeric 
conformation. With this optimized method, up to 28 mg dimeric 14-3-3h was obtained from 2 







Figure 4.3 – Purification of recombinant 14-3-3h. 14-3-3h expressed in E. coli BL21 (DE3) Star was 
purified by GST-glutathione affinity chromatography and subsequent SEC on the HiLoad Superdex 75 pg 
16/600 column, yielding 14-3-3h of high purity. a) The elution profile from final SEC purification yielded 
one peak, representing the pure 14-3-3h. b) SDS-PAGE analysis revealed a decrease in size from ~50 kDa 
prior to cleavage of the GST tag, to the final size of 28 kDa in the cleaved sample (red arrows). 
Contaminations in the cleaved sample were successfully removed by subsequent SEC to yield the fully 
purified 14-3-3h, as seen in the single band in the 14-3-3h sample.  
 
 
4.2 NUCLEAR MAGNETIC RESONANCE EXPERIMENTS  
 
4.2.1 Analyzing the a-Synuclein fingerprint spectrum  
In order to obtain a fingerprint of aS, a 2D 1H15N HSQC experiment was acquired on a 180µM 
13C15N-labeled aS sample and processed in TopSpin (see Section 3.5 for details). The resulting 
HSQC spectrum of cross-peaks, correlating backbone and sidechain 15N nuclei with 1H nuclei 
through a single bond, thus provided a fingerprint of the aS protein (Figure 4.4). Due to the 
high number of detected cross-peaks (140), excluding false peaks (noise) and correlations likely 
representing side chains containing N-H bonds (Figure 4.4, circled), the spectrum of aS in pH 
6.0 was deemed to be of satisfactory quality. This spectrum gave a representation of close to all 
140 amino acids constituting monomeric aS, whereas aS in pH 6.8 and 7.4 resulted in lower 
sensitivities (see Supplementary Data for spectra overlay). By comparing chemical shifts with 
an existing aS assignment from BMRB (Entry 6968)61, backbone residues were also assigned 
to cross-peaks with more distinct 1H and/or 15N d values, displayed in Figure 4.4. Importantly, 
the fingerprint was used as an indication of the degree of folding; the peaks were more 
congregated rather than widely dispersed, with rather similar 1H chemical shifts (Figure 4.4, 1H 
a) b) 
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d-axis). This further indicates a similar electron shielding environment for all residues, a 
phenomenon more often occurring when a protein is in an unfolded state.  
 
 
Figure 4.4 – 2D HSQC spectrum from 13C15N -labeled a-Synuclein (aS) at pH 6.0. The HSQC fingerprint 
of 180 µM 13C 15N-labeled monomeric aS detected 140 cross-peaks, representing the amino acid residues of 
the protein. Closely dispersed peaks along the F2 (1H chemical shift, d) and F1 (15N chemical shift, d) axis 
are indicates of an unfolded protein, corresponding to the intrinsically disordered native state of aS. Cross-
peaks representing side-chain H–N correlations are circled. Data were collected at 25°C on the 850 MHz 
Bruker Advanced III HD Spectrometer.  
 
1
H d  [ppm] 
15 N






Ser129 Ser9 Thr59 
 40 
4.2.2 Improving the fingerprint spectrum of 14-3-3h  
 
Various NMR experiments were acquired on 13C15N-labeled (double-labeled) and 2H13C15N-
labeled (triple-labeled) 14-3-3h to obtain a fingerprint, and the resulting spectra were processed 
in TopSpin (see Section 3.5 for details). Firstly, a 2D 1H15N HSQC experiment was acquired 
on 264 µM double-labeled 14-3-3h, which after processing yielded the 2D HSQC spectrum 
presented in Figure 4.5. However, this labeling and experiment (see Table 3) produced a 
spectrum of poor quality despite the high protein concentration and purity of the sample. 
Compared to the total of 246 residues comprising 14-3-3h50, very few cross-peaks were 
detected. Excluding the peaks that likely represented sidechains (Figure 4.5, circled), only 24 
cross-peaks appeared in the HSQC spectrum – the fold could therefore not be evaluated based 
on this result, nor could a backbone assignment be performed. Given the considerable size and 
dimeric structure of 14-3-3h, further optimizations to the experimental procedure and 
acquisition parameters were required to obtain more sensitive signal detection for this protein.  
 
 
Figure 4.5 – 2D HSQC spectrum of 13C15N-labeled 14-3-3h. 1H15N HSQC experiments (10 scans) were 
acquired on 264 µM 13C15N-labeled 14-3-3h. Excluding sidechain correlations, this fingerprint spectrum 
detected 24 cross-peaks, representing 24/246 residues in 14-3-3h. Cross-peaks likely representing sidechain 
correlations are circled. Data were collected at 25°C on the 850 MHz Bruker Advanced III HD Spectrometer. 
15 N
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To improve the 14-3-3h fingerprint spectrum, we attempted to decrease the relaxation rates by 
labeling the protein with 2H in addition to 13C and 15N (triple-labeled). Furthermore, a 1H15N 
TROSY-HSQC experiment was performed in addition to the standard 1H15N HSQC to 
compensate for the fast relaxation rates58, and the number of scans increased to 224 scans per 
experiment (see Table 3). However, interruptions in the protein purification process caused the 
protein sample quality to decrease, yielding an estimated protein concentration of 50 µM triple-
labeled 14-3-3h. Despite the lowered sample protein concentration, processed HSQC and 
TROSY-HSQC spectra still revealed an improved signal detection, presented as an overlay of 
spectra in Figure 4.6. Triple-labeling the protein and increasing the number of scans resulted in 
an HSCQ spectrum where 29 cross-peaks were detected (blue), excluding the sidechain 
correlations (circled). Applying TROSY-HSQC to the same sample did not lead to the detection 
of sidechain correlations, but further increased the sensitivity for backbone signals; 36 cross-
peaks appeared in the TROSY-HSQC spectrum (green), though slightly shifting the peaks. 
Moreover, the detection of these additional residues allowed for an estimation of the protein 
fold. The wider dispersion of cross-peaks along the 1H d axis in Figure 4.6 suggests a larger 
variation in nuclei chemical environments, corresponding to the spectrum of a folded protein. 
However, the improved TROSY-HSQC spectrum obtained in this study did not detect a 
sufficient number of cross-peaks to perform a 14-3-3h backbone assignment required for 





Figure 4.6 – Overlay of 2D HSQC and 2D TROSY-HSQC spectra of 2H13C15N-labeled 14-3-3h. 1H15N 
HSQC and TROSY-HSQC experiments (224 scans) were acquired on 50 µM 2H13C15N-labeled 14-3-3h and 
processed in TopSpin 4.0.7. The HSQC spectra (blue) detected 29 cross-peaks representing backbone 
correlations, as well as certain sidechain correlations (circled). The TROSY-HSQC spectrum detected seven 
additional peaks, improving the sensitivity and removing the side chain correlations. The less closely 
dispersed cross-peaks indicates a folded protein structure. Data were collected at 25°C on the 850 MHz 
Bruker Advanced III HD Spectrometer. 
 
 
4.3 THT-MONITORED a-SYNUCLEIN AGGREGATION ASSAYS   
 
Under the conditions of shaking and a temperature of 37°C, aS can self-associate and form 
fibrillar aggregates in vitro54. However, there are indications that the 14-3-3h isoform could 
affect the kinetics of this process by suppressing fibril formation9 (see Section 1.7.2). To study 
the effects of 14-3-3h on aS aggregation, ThT-monitored aggregation assays were performed 
with aS in the presence of 14-3-3h (see Section 3.6.2 for details). Due to the b-sheet dependent 
fluorescence of ThT, the resulting fluorescence signals could be used as a measure of the degree 
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4.3.1 Analysis of a-Synuclein fibrillation curves    
Aggregation assays of aS and 14-3-3h yielded one fibrillation curve per sample well, showing 
the ThT fluorescence intensity over time for each well in a sample (see Section 3.6.2). After 
data accumulation, the raw fluorescence data obtained with FLUOStar Optima Microplate 
Fluorescence Reader was processed with MatLab. Two of the replicates did not yield applicable 
results, as no fibrillation was observed for the aS positive controls. Only one replicate was 
therefore obtained for the BSA and FA-free BSA control samples within the time-restrictions 
of the project. Typical examples of fibrillation curves are displayed in Figure 4.7 a-d, which 
shows an apparent difference in aS fibrillation between the absence (a) and presence (b-d) of 
14-3-3h. On initial observation of the fibrillation curves alone, the fluorescence signal in 100 
µM aS appeared to increase early on and with steep slopes in all replicates (see Supplementary 
data for all fibrillation curves). Addition of 10, 20 and 55µM 14-3-3h seemingly caused a 
notable delay in the starting points and a decrease in the slope of the curves, indicating an 
attenuating effect on aS aggregation. However, further processing in the form of model fitting, 
parameter extraction and statistical analysis was required to confirm initial observations. Fitting 
of individual curves and extraction of aggregation parameters were therefore performed based 
on these fibrillation curves.  
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Figure 4.7 – ThT-monitored a-Synuclein (aS) fibrillation curves in the absence and presence of 14-3-3h. 
The aggregation of aS was monitored by the fibril-dependent fluorescence of ThT, creating a fluorescent 
signal increasing with fibril growth. Samples were prepared with 100 µM aS and 5 µM ThT in each sample, 
and 10-55 µM of 14-3-3h, with 15 wells/sample. Data were collected with FLUOStar Optima Microplate 
Fluorescence Reader. The selection of fibrillation curves shows the development of ThT fluorescence and 
thus fibrillation in a) 100 µM aS, b) aS + 10 µM 14-3-3h, c) aS + 20 µM 14-3-3h, and d) aS + 55 µM 14-
3-3h. Fibrillation appeared to decrease by the addition of 14-3-3h, seen in the increasing difference from a) 
to d).  
  
4.3.2 Extraction of kinetic parameters from the two-step aggregation model   
From the characteristic sigmoidal growth profile of typical aS aggregation and fibril growth, 
two kinetic parameters were extracted; the fibrillation constant, n, describing the rate of 
fibrillation (the slope), and the lag time, tn, describing the time until fibrillation occurs (see 
Section 3.6.2). After processing of the fluorescence signals, individual fibrillation curves of all 
wells from each sample were processed by normalizing the fluorescence signal and fitting the 
data to a two-step model (Section 3.6.2, Equation 1 and 2). This resulted in a sigmoidal fit, an 
example of which is displayed in Figure 4.8, a (red). Hence, n  and tn could be extracted directly 
from the fits for all samples with fits of satisfactory quality (r2 > 0.95). However, this fit proved 
a) b) 
c) d) 
aS aS + 10 µM 14-3-3h 
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unattainable for some of the curves in question (example in Figure 4.8, b), e.g. from wells in 
which the fluorescence signals remained approximately the same throughout the assay. 
Consequently, the number of successful fits differed from the total amount (Table 4).   
 
Figure 4.8 – Normalized single fibrillation curves fitted to the two-step aggregation model. Fibrillation 
curves from samples containing aS and 14-3-3h were fitted to a sigmoidal model representing the 
aggregation of aS, to extract the rate constant n and the lag time tn. The quality of the fits was evaluated 
based on their r2-value, and fits with r2 > 0.95 were deemed satisfactory. Displayed are examples of a high 
quality fit in a sample of 100 µM aS, yielding a sigmoidal fit and an r2 = 0.995 of the fitted curve (a, red 
line), and an example of curve which fitted poorly to the data, as seen by the horizontal fit line (red) and the 






























Table 4: Proportion of successful fits in each sample type  
Sample Successful fits/Total amount of fits 
100 µM aS  42/45 
aS + 55 µM BSA 5/15 
aS + 55 µM FA-free BSA 15/15 
aS + 10 µM 14-3-3h 25/45 
aS + 20 µM 14-3-3h 25/45 
aS + 55 µM 14-3-3h 21/45 
 
 
4.3.3 The effects of 14-3-3h on the lag time of a-Synuclein fibrillation   
 
To assess the changes in fibrillation rates and/or lag times, the mean values of extracted 
parameters n and tn for each sample were normalized to the positive control (100 µM aS), to 
assess whether any change in fibrillation rates and/or lag times occurred. On initial comparison 
of the different mean tn values, the most prominent effect was seen for the addition of 20 µm 
14-3-3h. This caused an apparent 139% increase in fibrillation lag time compared to the aS 
control. Similarly, 10 µM 14-3-3h caused an apparent 121% increase, while 55 µM 14-3-3h 
increased the lag time by 66% compared to the control (Figure 4.9). These observations suggest 
that 14-3-3h indeed slows the onset of aS fibrillation and that this effect could be dose 
dependent. However, statistical analysis revealed no significant differences in lag times 
between the aS control and aS supplemented with 14-3-3h, nor between the different dosages 
of 14-3-3h (Welch t-tests; n=3; P > 0.05, see Supplementary data for all statistical parameters). 
Nevertheless, the observed difference, though not significant in this study, was deemed 
noteworthy and possibly interesting for further studies with a greater number of replicates. 
While the control samples with BSA and FA-free BSA were more similar to the aS positive 
control, these results were considered inconclusive, given that only one replicate was obtained, 




Figure 4.9 – The effect of 14-3-3h on the lag times of a-Synuclein (aS) fibrillation. Normalized mean lag 
times, tn, of aS fibrillation from the different samples were extracted from model fits based on fibril-
dependent ThT-fluorescence. 100 µM aS was present in all samples. Mean tn values for each sample were 
normalized with respect to the aS positive control. Despite the apparent increase in lag time as a result of 
14-3-3h,  no statistically significant differences were detected between any of the samples (Welch t-tests; 
n=3; P > 0.05).  
 
4.3.4 The effects of 14-3-3h on the rate of a-Synuclein fibrillation  
 
Regarding the rates of aS fibrillation, the results immediately revealed a change resulting from 
the presence of 14-3-3h. Upon observation of the normalized mean n values (Figure 4.10), the 
fibrillation rates decreased by more than 50% from the aS control in samples containing14-3-
3h, suggesting that the presence of 14-3-3h slows the rate of aS fibrillation. Moreover, 
statistical analysis showed that 14-3-3h in concentrations of 10 and 55 µM significantly 
decreased the rate of aS fibrillation by 58 and 68% compared to aS control, respectively 
(Welch t-test; n=3; P < 0.05*, see Supplementary data). Furthermore, there were no significant 
differences between the effects observed by addition of 10 and 55 µM 14-3-3h, indicating that 
an increase in the 14-3-3h dosage is not necessarily proportional to the decrease in fibrillation 
rate (Welch t-test; n=3; P > 0.05). 20 µM 14-3-3h did not yield a significant decrease from the 




























standard deviation and variance in the n values rather than that there was no actual influence, 
implying that further studies are necessary to achieve a conclusive result. Interestingly, BSA 
appeared to have the greatest effect on the aS fibrillation rate, decreasing the rate by 87%, 
whereas the addition of FA-free BSA did not seem to lower the rate to any great extent. 
Although this could be an indication of the fatty acids in the BSA interacting with aS and 
lowering the fibrillation rate, one replicate was not enough to perform statistical analysis, as 
previously mentioned. Results with BSA and FA-free BSA were therefore deemed 
inconclusive. Hence, results with 14-3-3h could not be compared to any control samples in 




Figure 4.10 – The effect of 14-3-3h on a-Synuclein (aS) fibrillation rates. The normalized mean fibrillation 
rates, n, of aS aggregation from the different samples were extracted from model fits based on fibril-
dependent ThT-fluorescence. 100 µM aS was present in all samples. 10 and 20 µM 14-3-3h significantly 
decreased the aS fibrillation rates compared to the aS positive control (Welch t-tests; n=3; P < 0.05*). The 
suppressing effects of 14-3-3h on aS fibrillation rates did not prove to be dose dependent (Welch t-tests; 

























4.3.5 Cumulative analysis of a-Synuclein aggregation and the effects of 14-3-3h 
 
In addition to the fibrillation curves and kinetic parameters, the wells from each replicate were 
analyzed using an approach that is able to handle the stochastic nature of aS aggregation onset 
and propagation54 (see Section 3.6.2). This analysis is based on tracking the cumulative number 
of positive wells in each sample for each experimental replicate. To find the total percentage of 
aggregation-positive wells per sample, a threshold of a fluorescence signal three-fold higher 
than the maximum noise was used.  
 
In addition to providing an overview of the total effects of 14-3-3h in different doses, this 
representation also highlighted the variation between the three replicates (Figure 4.11 a-c). In 
samples containing 14-3-3h, the total percentage of wells after ~140 hours ranged from 30-
100%, depending on the replicate. Nevertheless, notable differences were observed from the 
aS control samples. Whereas uninhibited aS increased in positive wells from 20-25 hours and 
rapidly reached 100%, aS containing 14-3-3h displayed no positive wells until 50-60 hours 
had passed. The transition from 0 to 100% also progressed at a slower pace in the 14-3-3h 
samples, altogether indicating that 14-3-3h could slow the total aggregation process of aS. We 
provided further statistical support for this assumption by obtaining the average percentage of 
positive wells (APPW) in each sample over time and normalizing it to the aS control (see 
Supplementary data). We found that 14-3-3h significantly decreased the APPW over time 
(Welch t-tests; n = 3; P < 0.05*), suggesting that 14-3-3h attenuates the overall aS fibrillation 
process. 55 µM 14-3-3h had the most prominent effect on aggregation, producing a 0.9-fold 
decrease in APPW from the aS control (Welch t-test; n = 3; P < 0.01**).  
 
In correspondence with the lowered rate of fibrillation resulting from BSA (Figure 4.10), the 
percentage of positive wells was also clearly affected by BSA (Figure 4.11, b), with < 20% 
aggregation positive wells. The striking difference between BSA and FA-free BSA also became 
clear in this representation, as the addition of FA-free BSA produced a curve nearly identical 
to the positive aS control (Figure 4.11, c). Moreover, FA-free BSA did not affect aS 
aggregation, while BSA yielded close to a 1-fold decrease in the APPW (see Supplementary 
data).   
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Figure 4.11 – Cumulative representation of a-Synuclein (aS) aggregation positive wells and the effects 
of 14-3-3h. aS aggregation were monitored by the fibril-dependent fluorescence of ThT, creating a 
fluorescent signal increasing with fibril growth. Cumulative analysis of each of the three experiment 
replicates was performed to find the percentage of aggregation positive wells/sample, i.e. where the 
fluorescent signal ascended three-fold of the noise. Panel a) – c) displays results from the first, second and 
third replicate, respectively. The percentage of positive wells was observed to decline in samples containing 
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4.4 SURFACE PLASMON RESONANCE INTERACTION STUDIES  
 
There are several indications that 14-3-3h interacts with aS in the parkinsonian brain (Section 
1.7.2), and our results from aggregation assays (Section 4.3) implied that this interaction could 
attenuate the aggregation of aS. However, the properties of this interaction have yet to be fully 
described. SPR was utilized to characterize the binding of 14-3-3h to monomeric aS. The 
interaction between 14-3-3h in solution and monomeric aS immobilized on a CM5 sensor chip 
was reported in arbitrary response units (RU) to determine the affinity of binding (see Section 
3.7). HBS-EP+ buffer was injected onto the chip to control the occurrence of non-specific 
binding. The response (RU) upon each injection was detected to evaluate whether binding 
occurred. Injections of the buffer control yielded no response, indicating no non-specific 
binding to the chip. All buffer injections yielded RU equal to or below zero (Figure 4.12). 
Regarding the binding between 14-3-3h and the monomeric aS, negative values of 
approximately -15 RU were detected as a response to the injections of 0.5-1.0 µM, indicating 
that no binding had occurred (Figure 4.12). Increasing 14-3-3h concentrations to 2.5-10 µM 
yielded little increase in the detected response, with 0.55 RU for 10 µM 14-3-3h. Hence, the 
response and difference from 14-3-3h to the buffer control was deemed dismissible, suggesting 
that 14-3-3h was not able to bind monomeric aS. However, only one experiment was 
performed, leaving statistical analysis infeasible.  
 
 
Figure 4.12 – Interaction between 14-3-3h and a-Synuclein analyzed by SPR. 14-3-3h in concentrations 
of 0.5-10 µM were injected onto 1900 RU of monomeric aS immobilized to a CM5 sensor chip and the 
reference cell. Binding analysis was performed on the BiaCore T200 with flow rate 25 µl/min, 240 s contact 
time, 600s dissociation time, 30 s stabilization period and the chip was regenerated with 10 mM Glycine pH 




































Fibrillar αS aggregates have been discovered to be the primary component of LBs, insoluble 
neuronal inclusions characteristic of Parkinsonian brains. The misfolding and aggregation of 
αS, preceding the formation of LBs, is thus considered central to PD6. However, it remains 
enigmatic why this intrinsically disordered protein misfolds and aggregates, and how to prevent 
it. In this context, the 14-3-3 family of scaffold proteins with chaperone-like activities have 
come of interest as possible suppressors of αS aggregation47. In particular, the 14-3-3η isoform 
was discovered to interact with αS in a way that attenuates and reroutes its fibrillation, and has 
been co-immunoprecipitated with αS from Parkinsonian brains9,52. In this study, we aimed to 
elucidate upon the effects of 14-3-3η on the kinetics of αS aggregation in vitro, employing ThT 
aggregation assays and subsequent evaluation of fibrillation curves. We further attempted to 
characterize the binding properties of the two proteins utilizing NMR and SPR.  
 
5.1 α-SYNUCLEIN AND 14-3-3h NMR SAMPLES INDICATE POTENTIAL FOR 
FURTHER CHARACTERIZATION   
 
The success of NMR spectroscopy relies on several factors. Firstly, the sample quality affects 
the quality of the spectra as well. A sufficient protein concentration, optimal buffer conditions 
and the correct isotope labeling scheme are all required in a high-quality sample62. Moreover, 
intrinsic protein properties such as size and conformation affect the resolution and sensitivity 
of an NMR experiment57. In this study, NMR spectroscopy was employed to obtain HSQC 
fingerprints and verify the protein fold of αS and 14-3-3h. Such HSQC experiments are 
generally the first step and a prerequisite for proceeding with analysis in protein NMR62. 
Moreover, it was attempted to obtain a 14-3-3h fingerprint spectrum satisfactory for backbone 
resonance assignment to be used in future NMR interaction studies.  
 
5.1.1 HSQC fingerprint of a-Synuclein confirms its disordered state 
 
HSQC experiments on uniformly 180 µM 13C15N-labeled αS resulted in a high-quality 
fingerprint spectrum with all 140 residues represented (Figure 4.4), with the exception of 
prolines, in addition to side chains containing the N-H amine bond. Because residues in an 
unfolded protein will experience rather similar chemical environments, their chemical shifts 
will be similar as well. This will in turn produce a spectrum where the cross-peaks are not as 
dispersed as for a folded protein with a tertiary structure. The aS HSQC spectrum with closely 
dispersed cross-peaks therefore indicates that the protein is indeed unfolded, as expected from 
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the intrinsically disordered state of monomeric αS. Used as a quality assessment for products 
of the αS expression system, this supports that the expression system does yield monomers in 
solution. Moreover, the chemical shifts of the cross-peaks could be used to complete an αS 
backbone assignment if triple-resonance experiments are acquired. This would allow for more 
accurate assignment, as triple-resonance experiments enable better cross-peak dispersion, 
sequential connectivity between amino acid residues and better differentiation between amino 
acid type based on the 13C chemical shift. However, the time restrictions of this project did not 
allow for such experiments, and the current partial assignment is based only on 1H and 15 
chemical shifts and an existing assignment by Bermel et al61.  
 
5.1.2 2H-labeling and TROSY-HSQC improves the sensitivity of 14-3-3h signal detection  
 
The 1H15N HSQC experiments acquired on 13C15N-labeled (double-labeled) 264 µM 14-3-3h 
yielded a fingerprint spectrum of poor quality, with only 24/246 backbone residues detected 
(Figure 4.5). As such, the fold could not be evaluated from the insufficient number of cross-
peaks. This low sensitivity can be attributed to the size of 14-3-3h. While 13C15N -labeling and 
10 scans per experiment proved sufficient to detect the αS backbone signals, the 28 kDa 14-3-
3η is a considerably larger protein, comprising 246 residues50. For large proteins, a high number 
of 1H nuclei and slow tumbling makes dipole-dipole relaxation pathways more efficient than 
for smaller proteins. As a result, the relaxation rates increase, which in turn causes signal 
broadening to the point where individual residues are difficult to detect (Section 1.8.2)57. 
Moreover, 14-3-3h’s dimeric state likely posed another challenge for this type of experiment, 
as the monomer-dimer equilibrium may reduce spectral quality63.  
 
To combat the issues of protein size, 14-3-3h was expressed with 2H in addition to 13C and 15N 
(triple-labeling) to interfere with the 1H nuclei interactions, yielding a sample of ~50 µM 14-3-
3h. This has the effect of thinning out the 1H nuclei responsible for the efficient relaxation57. 
Furthermore, the number of scans was increased to 224 scans per experiment (Table 3) and 
1H15N TROSY-HSQC was employed to compensate for the fast relaxation rates58. With these 
methodological optimizations, we were able to get fingerprint spectra with 29/246 and 36/246 
residues represented in the HSQC and TROSY-HSQC spectra, respectively (Figure 4.6). 
Although this is a relative improvement from the HSQC of the double-labeled sample, the 
TROSY-HSQC spectrum quality remained too poor to extend the data accumulation to triple-
resonance experiments for backbone assignment. However, we suggest that this is attributed to 
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the low protein concentration in the sample, which lowers the sample quality, rather than the 
experimental approach.  
 
Regardless, we propose that triple-labeling and TROSY-HSQC experiments described in this 
study can be employed to achieve a satisfactory fingerprint spectrum of 14-3-3h if a more 
concentrated triple-labeled sample is prepared. Indeed, a similar approach was utilized in a 
study of 14-3-3z by Killoran et al64, who performed a 14-3-3z assignment (BMRB: 25231) and 
binding studies based on the 1H15N TROSY-HSQC spectrum. Using this assignment as a 
reference, a proper 14-3-3h fingerprint spectrum could provide a partial backbone assignment 
also for 14-3-3h, although each assignment should be verified using the appropriate triple-
resonance techniques, namely HNCA, HNCACB, HNCOCACB. A complete assignment could 
then be used to identify residues involved in aS binding by titrating with unlabeled aS, then 
identifying the residue-specific changes in the 14-3-3h fingerprint. 
 
 
5.2 14-3-3η AFFECTS THE KINETICS OF a-SYNUCLEIN FIBRILLATION  
 
Previous studies have implicated 14-3-3η as an interaction partner and influencing factor of αS 
aggregation (see Section 1.7). To study whether 14-3-3η affects the kinetics of αS fibrillation, 
we utilized ThT-monitored aggregation assays with αS in the absence and presence of 14-3-3η. 
Fluorescence curves processed from raw experimental data revealed a clear tendency of 
decreased fibrillation onset and rate as a result of 14-3-3η (Figure 4.7 and Supplementary data). 
However, no conclusions could be drawn from these curves alone, as the stochastic nature of 
fibrillation caused each replicate to differ considerably. The data was therefore fitted to a two-
step model (Section 3.6.2) to obtain kinetic parameters and form the basis for a more tangible 
approach to data evaluation. 
 
5.2.1 Preliminary curve fitting data suggests 14-3-3h may suppress fibrillation 
 
Fitting the normalized fluorescence curves to a two-step model (Section 3.6.2) provided curve 
fits from which kinetic parameters tn (lag time) and ν (fibrillation rate constant) could be 
extracted. Although several fits proved not successful for parameter extraction, this alone could 
indicate attenuating effects of 14-3-3η. When comparing the proportion of high-quality fits in 
the αS control samples and samples containing 14-3-3η (Table 4), unperturbed αS aggregation 
gives fluorescence data that fit well to the sigmoidal model and thus a large proportion of 
successful fits. Conversely, the presence of 14-3-3η appears to give data less suitable for the 
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sigmoidal fit, and a flattened curve. This suggests that 14-3-3η in some cases may have greatly 
impeded fibrillation onset, i.e. that the lag time exceeded the assay time, or even that 14-3-3h 
suppressed fibrillation completely. This observation is further supported by Plotegher et al9, 
who found that the presence of 14-3-3h with aS caused a negligible increase in ThT 
fluorescence, and thus aS fibrillation. As such, extending the assay time could be beneficial to 
obtain a higher proportion of successful fits and thus a complete set of parameters from each 
replicate.    
 
5.2.2 14-3-3h Significantly attenuates fibrillation growth rates and overall fibrillation 
 
The extraction of kinetic parameters from the fitted curves enabled a more precise assessment 
of the experimental data. Preliminary comparisons of mean tn (lag times) normalized to the αS 
control indicated that 14-3-3η could increase the fibrillation lag time by up to 139% (Figure 
4.9), thus attenuating fibrillation onset. However, the effects of 14-3-3h on aS fibrillation lag 
time were not attenuating to a significant degree (Welch t-tests; n=3; P > 0.05), suggesting that 
14-3-3h does not interfere with aS fibrillation onset. Regardless, this non-significance could 
be due to an insufficient number of replicates in combination with the great variations between 
them. Given the large apparent effects observed in this study, 14-3-3h might have significantly 
prolonged the aS fibrillation lag time if the number of replicates and the assay time were 
increased to minimize statistical variations.  
 
Although 14-3-3h induced no significant changes in aS fibrillation onset, it significantly 
decreased the aS fibrillation rate (Welch t-tests; n=3, P <0.05*, Figure 4.10), indicating that 
14-3-3h interferes with secondary nucleation in the fibrillation process (see Section 1.4). 
Evaluation of mean fibrillation rates,n, normalized to the aS control revealed that 55 µM 14-3-
3h decreases the fibrillation rate by 68%. Interestingly, 10 µM 14-3-3h induced a similar drop 
in the fibrillation rate (58%), so the attenuating effects were not dose-dependent (Welch t-test; 
n = 3, P > 0.05). These results imply that 14-3-3h can significantly slow aS fibril growth even 
in aS:14-3-3h ratios of 10:1. As a ratio of 2:1 does not further decrease the growth rate, 14-3-
3h could have reached a saturation point as suggested by Plotegher et al9. However, it is also 
possible that the concentrations used in this study were too similar to yield any dose-
dependency. Performing additional experiments with 1:1, 1:2 and higher ratios would be 
needed to confirm these observations. Experiments with ratios of 15:1, 20:1 and lower would 
also be beneficial to explore the threshold at which 14-3-3h becomes attenuating.  
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Additionally, cumulative aggregation analysis of individual replicates showed the percentage 
of aggregation positive wells to remain 0% for an extended time in wells containing 14-3-3h 
compared to those containing aS alone (Figure 4.11). 14-3-3h was shown to significantly 
decrease the overall aggregation, represented by the APPW, for all ratios used in this study 
(Welch t-tests; n = 3, P < 0.05*, see Supplementary data), with the most prominent effect on 
APPW observed for 55 µM 14-3-3h (Welch t-test; n = 3; P < 0.01**). No significant differences 
were detected between the different 14-3-3h concentrations (Welch t-tests; n = 3; P > 0.5), 
further supporting that the attenuation by 14-3-3h is not dose-dependent. As this type of 
analysis takes the complete dataset into account, we obtained a more robust, though less 
specific, significance in the results as well. Furthermore, the variations between the replicates 
become clear in the high standard deviations (Figure 4.10) for each sample and the cumulative 
aggregation analysis of each replicate (Figure 4.11). This variation could be an explanation for 
why 20 µm 14-3-3h yielded no significant effect on aS fibril growth rates (Welch t-test; n = 3, 
P > 0.05). Because this concentration lies in the range between 10 and 55 µM, it is likely that 
this non-significant result was due to an insufficient number of replicates and large variances, 
similar to the tn results. We therefore propose that 14-3-3h attenuates the overall aggregation 
process through decreasing the fibril growth rate, and likely the fibrillation onset as well. 
 
In addition to samples with aS and 14-3-3h, BSA and FA-free BSA were added to aS to assess 
whether the attenuating effects were due to 14-3-3h or the addition of any protein in itself. The 
size of BSA (66 kDa) is roughly similar to the 14-3-3h dimer (56 kDa), with approximately the 
same pI of 4.7-5.0. Although only one replicate was obtained for each of these samples, the 
results demonstrated a clear difference in their effects on aS aggregation. While FA-free BSA 
produced lag times and fibrillation rates (Figure 4.9, Figure 4.10) similar to aS alone, BSA 
containing fatty acids decreased the fibrillation rate by 87% (Figure 4.10). The difference also 
becomes highlighted in the cumulative aggregation analysis; the addition of BSA caused a 
negligible percentage of aggregation positive wells, and FA-free BSA produced a curve similar 
to the aS control (Figure 4.11, b-c). These results are likely attributed to the FAs in BSA 
interacting with aS (see Section 1.5.1), and that this interaction has a great influence on its 
fibrillation. Hence, FA chains in solution could be a suppressing factor in aS aggregation, 
despite that short FA chains in the membrane have been suggested as strong aggregation 
inducers28, indicating that the organization of FAs is important for their influence on aS 
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aggregation. Moreover, the negligible effect of FA-free BSA suggests that 14-3-3h indeed 
causes the attenuation observed in this study. However, as one replicate does not yield any 
conclusive results nor statistical analysis, this cannot be stated with full confidence. 
Summarized, our results imply a role of 14-3-3h as an attenuating factor in aS fibrillation. 
However, ThT does not produce fluorescence signals until binding to b-sheets in the 
protofilaments and fibrils occur54. Therefore, these assays provide no information as to which 
aS aggregation stage 14-3-3h binds, or if it affects the oligomerization process. Using the 14-
3-3h NMR results obtained in this study (See Section 4.2.2 and 5.1.2) however, we are well 
positioned to expand our knowledge on this matter in the future.  
 
5.3 14-3-3h DOES NOT APPEAR TO BIND MONOMERIC a-SYNUCLEIN  
 
In addition to the effects of 14-3-3h on aS aggregation observed in this study, studies with 14-
3-3h and aS suggest that the two proteins interact9,52. To gain a more detailed understanding 
of this interaction, 14-3-3h and monomeric aS was investigated by SPR (see Section 3.7) to 
obtain accurate detection of a possible binding. Results from SPR binding analysis with 0.5-10 
µM 14-3-3h revealed no binding response (Figure 4.12), suggesting that 14-3-3h is unable to 
bind monomeric aS. Although only one replicate was obtained due to time restrictions of the 
project, this suggestion is supported by native PAGE analysis and NMR studies of aS and 14-
3-3h from Plotegher et al9. This study found that monomeric aS with 14-3-3h migrated as two 
distinct bands on a native PAGE, and that 14-3-3h did not affect the chemical shifts of 
monomeric aS, both indicative of no binding. However, their NMR approach could be 
improved, e.g. by analyzing peak volumes in addition to the configuration of the fingerprint. 
They further concluded with 14-3-3h being able to bind only to the oligomeric species of aS9. 
However, SPR studies by Sato et al52 demonstrated an interaction between 14-3-3h and aS 
monomers with a binding affinity Kd = 1.1 µM, although this result could be caused by oligomer 
contaminations in the interaction. The results in this study therefore support the assumption by 
Plotegher et al9 that 14-3-3h binds to oligomeric states of aS aggregation. This further implies 
that the interaction cannot affect aS oligomerization and primary nucleation (see Section 1.4), 
but further studies would be needed to confirm this with full confidence. Repeating the SPR 
experiments in this study with immobilized aS oligomers and additional replicates with 




5.4 IMPLICATIONS FOR PARKINSON’S DISEASE   
 
The accumulation and aggregation of aS are now considered integral parts of the mechanisms 
underlying PD6. Results from this study suggest 14-3-3h as a negative modulator of aS fibril 
onset and growth, which implicates an interesting role for this protein in PD pathology. Even 
in sub-stochiometric amounts of 10:1 and 2:1, 14-3-3h can decrease the aS fibrillation growth 
rate and possibly attenuate fibrillation onset in vitro, suggesting 14-3-3h as a possible 
neuroprotective factor in PD. While more extensive studies would be needed to validate this 
assumption, the study by Plotegher et al9 demonstrated a complete suppression of aS 
fibrillation in aS:14-3-3h ratios of 4:1 and reduced aS-induced toxicity by overexpressing 14-
3-3h, whereas the results in this study only demonstrated a delay in the fibrillation.  
 
Moreover, in vivo studies demonstrated an upregulation of 14-3-3h transcription in aging mice 
overexpressing aS65, indicating it may be part of a protective response to abnormal aS  
aggregation. Evidence that aS in overwhelming amounts could sequester 14-3-3h and thus 
cease its attenuating effects has also been suggested as a possible toxicity mechanism for aS 
oligomers9. Such sequestration could lead to the dysregulation of proteins normally regulated 
by 14-3-3h, and possibly other isoforms, thus depriving the cells of important regulatory 
functions. 14-3-3h is a suppressor of Parkin activity (see Section 1.7.2), a protein whose 
dysregulation is associated with PD52. Moreover, several 14-3-3 proteins, including 14-3-3h, 
have been discovered to bind and activate Tyrosine hydroxylase, a crucial enzyme in the 
biosynthesis of catecholamines like dopamine66,67,46. Hence, sequestration of 14-3-3h and 
possibly other isoforms could cause an un-timely activation of Parkin, and impairment of 
dopamine synthesis in PD. Interestingly, studies by Xu et al11 suggested that aS accumulation 
induces neuronal apoptosis mediated by endogenous dopamine in dopaminergic cell lines, 
creating a paradox as to whether impaired dopamine synthesis could actually be beneficial to 
the already damaged cells. However, they further observed that elevated levels of aS/14-3-3 
complexes increased neuronal vulnerability. 14-3-3s normally inactivate pro-apoptotic proteins 
like mitochondrial BAD and the Forkhead transcription factor. The sequestration into aS/14-
3-3 complexes could thus reduce anti-apoptotic activity and make the dopaminergic neurons 
more vulnerable to reactive oxygen species generated by dopamine metabolism11.  
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Altogether, observations in the literature as well as our own results could explain how 
overexpression of 14-3-3h reduces aS-induced toxicity47, and thus why it is upregulated as a 
response to aS overexpression. Contradictory to these findings and the results of this study, in 
vivo experiments by Yacoubian et al8 found 14-3-3h to be amongst 14-3-3 isoforms which did 
not affect aS aggregation nor reduce neurotoxicity. Further research on 14-3-3h is therefore 
required to uncover its exact role in PD pathology. Regardless, 14-3-3h appears to be intricately 




In this study, we aimed to investigate the influence of 14-3-3h on the kinetics of aS 
aggregation, and characterize the binding of 14-3-3h to aS. Our findings show 14-3-3h to 
decrease aS fibril growth rate by more than 50% in ratios of 10:1 and 2:1 (aS:14-3-3h). 
Although 14-3-3h did not induce significant changes in lag times, this can be attributed to the 
insufficient number of replicates and large variations resulting from the stochastic nature of 
fibrillation onset. Moreover, 14-3-3h yielded several flattened ThT fluorescence curves 
indicative of no aS fibrillation, not included in the statistical analysis. 14-3-3h also decreased 
the APPW over time, supporting that its influence on aS aggregation affects both fibrillation 
onset and growth in vitro. However, SPR experiments detected no interaction between 14-3-3h 
and monomeric aS, suggesting that it must interact with oligomeric species formed before 
fibrillation occurs. Despite that only one SPR replicate was obtained, this result is supported by 
NMR results from Plotegher et al9. The exact nature of this interaction remains unknown and 
merits further exploration. Regardless of mechanism, aS–14-3-3h interaction could provide an 
explanation for the 14-3-3h upregulation observed in vivo for mice overexpressing aS. 
Sequestration of 14-3-3h into aS fibrils also provides a possible toxicity mechanism for aS 
oligomers in PD.   
 
To summarize, we found that 14-3-3h significantly attenuates the overall aS fibrillation 
process. We propose that 14-3-3h attenuates aS fibrillation rates and probably interferes with 
fibrillation onset through interaction with aS oligomeric species. We further conclude that a 
satisfactory fingerprint spectrum of 14-3-3h can be obtained through 2H13C15N triple-labeling 
and 1H15N TROSY-HSQC, enabling for future binding site analysis. Lastly, we believe 14-3-
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3h could emerge as a biomarker or even a therapeutic target in PD based on its connection to 
aS aggregation, providing a biomedical motivation for more extensive studies of this 
chaperone-like protein.  
 
  
5.6 FUTURE PERSPECTIVES 
 
The 14-3-3 family of proteins have been implicated in several human diseases, including PD38. 
Several isoforms have been detected in LBs from parkinsonian brains47, and some isoforms are 
found to have neuroprotective effects both in vitro and in vivo8. The 14-3-3h isoform is one of 
the only isoforms demonstrated to directly influence the aS aggregation process9. This study 
thus focused on uncovering the direct effects of 14-3-3h on aS aggregation kinetics, and 
explore the interaction between 14-3-3h and aS. Although our findings indicate an attenuating 
role for 14-3-3h, further research is needed to fully understand how this isoform could be 
involved in aS aggregation and the pathological mechanisms in PD.  
 
To gain a better understanding of 14-3-3h and its role in aS aggregation, it would be beneficial 
to repeat the in vitro aggregation assays of this study, acquiring a sufficient number of replicates 
to provide more statistical rigor. Implementing a wider range of 14-3-3h concentrations and 
longer experiment running times could provide new insights into critical aS:14-3-3h ratios for 
suppression of fibrillation. Furthermore, conducting aggregation assays with the remaining 14-
3-3 isoforms would be an interesting approach to uncover whether the observed effects are 
isoform-specific to 14-3-3h. Moreover, studies of 14-3-3ζ have suggested that the capacity of 
its chaperone activity is greatly increased by the monomer configuration44,45. Hence, repeating 
the aggregation assays with monomeric 14-3-3h, e.g. by removing the dimerization site, could 
be an interesting approach to study how monomeric 14-3-3h compares to the dimer 
configuration with regards to aS aggregation.  Additionally, the association of aS with lipids 
have been shown to greatly influence its aggregation propensity26,27, demonstrated in this study 
by the strikingly different effects of BSA and FA-free BSA on aS fibrillation. Hence, it could 
be useful to repeat the experiments using lipids in the samples to investigate whether lipid 
association could affect the attenuation by 14-3-3h on aS aggregation.   
 
Previous attempts have been made by Sato et al52 and Plotegher et al9 to determine how, and 
with what affinity, 14-3-3h binds aS. In this study, we attempted to utilize SPR and NMR to 
 61 
uncover the properties of the interaction, however, time restrictions prevented the completion 
of these experiments. Proceeding with SPR experiments on 14-3-3h and aS 
monomers/oligomers could be the next step in determining binding affinities. Moreover, an 
interesting way to locate the 14-3-3h binding site would be to complete a backbone assignment 
using the triple-labeling and NMR scans described in this study, as well as aquiring triple-
resonance experiments. Acquiring scans of 14-3-3h in the absence and presence of 
monomeric/oligomeric aS could then be used to detect the residues displaying the greatest 
chemical shift perturbations or reduction in signal intensities/peak volume, and thus are likely 
part of the binding site. Lastly, it would be interesting to repeat both aggregation and interaction 
experiments with aS phosphorylated at S129. Not only are the majority of 14-3-3 target 
proteins phosphorylated, but aS phosphorylation at S129 is the most prominent PTM observed 
in LBs and associated with aS aggregation29. Performing these experiments with 
phosphorylated aS would therefore elucidate upon the role of this PTM in the interaction 
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7. SUPPLEMENTARY DATA  
 




Figure 7.1 – Overlay of 2D HSQC spectra from 13C 15N-labeled aS in various pH conditions. The 
HSQC fingerprints of 180 µM 13C15N-labeled aS at pH 6.0 (blue), 6.8 (red) and 7.4 (purple) were similar 
in their sensitivity and detection of cross-peaks. Closely dispersed peaks along the F2 (1H chemical shift, 
d) and F1 (15N chemical shift, d) axis are indicates of an unfolded protein, corresponding to the 
intrinsically disordered native state of aS. However, certain peaks were only detected in aS pH 6.0 – 
this pH value was thus used for further NMR experiments. Data were collected at 25°C on the 850 MHz 
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Figure 7.2 – ThT-monitored aS fibrillation curves in the absence and presence of 14-3-3h, 1st replicate. The 
aggregation of aS was monitored by the fibril-dependent fluorescence of ThT, creating a fluorescent signal 
increasing with fibril growth. Samples were prepared with 100 µM aS and 5 µM ThT in each sample, and 10-55 
µM of 14-3-3h, with 15 wells/sample. Data were collected with FLUOStar Optima Microplate Fluorescence 
Reader. The selection of fibrillation curves shows the development of ThT fluorescence and thus fibrillation in a) 
100 µM aS, b) aS + 10 µM 14-3-3h, c) aS + 20 µM 14-3-3h, and d) aS + 55 µM 14-3-3h.  
a) b) 
c) d) 
aS aS + 10 µM 14-3-3h 















Figure 7.3 – ThT-monitored aS fibrillation curves in the absence and presence of 14-3-3h, 2nd replicate. 
The aggregation of aS was monitored by the fibril-dependent fluorescence of ThT, creating a fluorescent signal 
increasing with fibril growth. Samples were prepared with 100 µM aS and 5 µM ThT in each sample, and 10-
55 µM of 14-3-3h, with 15 wells/sample. Data were collected with FLUOStar Optima Microplate Fluorescence 
Reader. The selection of fibrillation curves shows the development of ThT fluorescence and thus fibrillation 
in a) 100 µM aS, b) aS + 10 µM 14-3-3h, c) aS + 20 µM 14-3-3h, and d) aS + 55 µM 14-3-3h. 
a) b) 
c) d) 
aS aS + 10 µM 14-3-3h 



















aS + 10 µM 14-3-3h aS  
aS + 20 µM 14-3-3h aS + 55 µM 14-3-3h 
Figure 7.4 – ThT-monitored aS fibrillation curves in the absence and presence of 14-3-3h, 3rd replicate. The 
aggregation of aS was monitored by the fibril-dependent fluorescence of ThT, creating a fluorescent signal 
increasing with fibril growth. Samples were prepared with 100 µM aS and 5 µM ThT in each sample, and 10-55 
µM of 14-3-3h, with 15 wells/sample. Data were collected with FLUOStar Optima Microplate Fluorescence 
Reader. The selection of fibrillation curves shows the development of ThT fluorescence and thus fibrillation in a) 






Table 7.1a: Mean fibrillation lag times (tn) normalized to aS control 
Sample  100 µM 
aS 
aS + 55 µM 
BSA 
aS + 55 
µM FA-
free BSA 
aS + 10 µM 
14-3-3h 
aS + 20 µM 
14-3-3h 
aS + 55 µM 
14-3-3h 
tn, 1st replicate (%)  100 - - 279.7 337.7 139.5 
tn, 2nd replicate (%) 100 115.8 - 162.9 148.6 159.0 
tn, 3rd replicate (%)  100 - 81.0 220.4 232.9 199.6 
       
Mean tn (%) 100 115.8 81.0 221.0 239.8 166.1 












a) b) aS + FA-free BSA  aS + BSA 
Figure 7.5 – ThT-monitored aS fibrillation curves in the presence of BSA and FA-free BSA protein controls. The 
aggregation of aS was monitored by the fibril-dependent fluorescence of ThT, creating a fluorescent signal increasing 
with fibril growth. Samples were prepared with 100 µM aS and 5 µM ThT in each sample and 15 wells/sample. Data 
were collected with FLUOStar Optima Microplate Fluorescence Reader. The fibrillation curves show fibrillation 
development of a) aS + 55 µM FA-free BSA, from the 3rd replicate, and b) aS + 55 µM BSA, from the 2nd replicate.   
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Table 7.1b: P-values from statistical analysis (Welch t-test) of mean fibrillation lag 
times (tn), significance level a = 0.05 
 
  100µM aS aS + 10µM 14-
3-3h 
aS + 20µM 14-
3-3h 
aS + 55µM 14-
3-3h 
100 µM aS 
 
-    
aS + 10µM 14-3-3h 
 
0.07 -   
aS + 20µM 14-3-3h 
 
0.1 0.8 -  





Table 7.2a: Mean fibrillation rates (n) normalized to aS control   
Sample  100 µM 
aS 
aS + 55 µM 
BSA 
aS + 55 
µM FA-
free BSA 
aS + 10 µM 
14-3-3h 
aS + 20 µM 
14-3-3h 
aS + 55 µM 
14-3-3h 
n, 1st replicate (%)  100 - - 68.5 78.5 55.3 
n, 2nd replicate (%) 100 12.7 - 28.0 22.8 25.3 
n, 3rd replicate (%)  100 - 97.6 30.2 21.1 14.3 
       
Mean n (%) 100 12.7 97.6 42.2 40.8 31.6 
Std. Dev  0 - - 22.7 32.7 21.2 
 
 
Table 7.2b: P-values from statistical analysis (Welch t-test) of mean fibrillation rates (n), 
significance level a = 0.05  
 
 100µM aS aS + 10µM 14-
3-3h 
aS + 20µM 14-
3-3h 
aS + 55µM 14-3-3h 
100 µM aS 
 
-    
aS + 10µM 14-3-3h 
 
0.04* -   
aS + 20µM 14-3-3h 
 
0.08_ 0.9 -  












Figure 7.6 – Average percentage of aggregation positive wells over 140 hr, normalized to aS control. 
The aggregation of aS were monitored over time by the fibril-dependent fluorescence of ThT, creating 
a fluorescent signal increasing with fibril growth. A cumulative analysis was performed to find the 
percentage of aggregation positive wells/sample, i.e. where the fluorescent signal ascended three-fold 
of the noise. The average percentages over time for each sample were normalized to the aS control. 14-





Table 7.3: P-values from statistical analysis (Welch t-test) of the average percentage of aggregation 
positive wells, significance level a = 0.05  
 
 100µM aS aS + 10µM 14-
3-3h 
aS + 20µM 14-
3-3h 
aS + 55µM 14-3-3h 
100 µM aS 
 
-    
aS + 10µM 14-3-3h 
 
0.02* -   
aS + 20µM 14-3-3h 
 
0.02* 0.9 -  





















 BSA 10 µM 
14-3-3h 
20 µM 
14-3-3h 
55 µM 
14-3-3h 
* * 
** 
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